[{"data":1,"prerenderedAt":2004},["ShallowReactive",2],{"newsletter-list":3},[4,385,538,870,1152,1334,1588,1859],{"id":5,"title":6,"author":7,"body":8,"date":376,"description":377,"extension":378,"meta":379,"navigation":380,"path":381,"seo":382,"stem":383,"__hash__":384},"newsletter\u002Fnewsletter\u002Fmicrobiomeeng.md","Engineering the Microbiome: How Scientists Are Turning Bacteria Into Living Medicines","Alana Lu",{"type":9,"value":10,"toc":363},"minimark",[11,16,35,39,42,45,48,51,54,57,67,73,77,80,83,86,94,97,100,107,111,115,118,121,124,127,130,134,145,148,151,154,161,168,171,174,177,180,187,190,193,196,203,207,211,214,217,220,231,234,241,245,249,252,255,258,261,264,267,270,274,277,280,283,286,289,296,300,304,307,310,313,316,319,323],[12,13,15],"h2",{"id":14},"in-brief","In Brief",[17,18,19,23,26,29,32],"ul",{},[20,21,22],"li",{},"The human microbiome contains trillions of microorganisms that influence digestion, metabolism, immunity, and other aspects of human health.",[20,24,25],{},"Scientists are engineering bacteria to detect biological signals, break down harmful molecules, and produce therapeutic substances inside the body.",[20,27,28],{},"Early clinical studies show that engineered microbes can perform specific biological functions in humans, moving the field beyond laboratory experiments.",[20,30,31],{},"A recent breakthrough demonstrated that researchers can control how an engineered bacterium colonizes the human gut—and later clear it—addressing one of the biggest challenges facing living medicines.",[20,33,34],{},"Although safety, genetic stability, manufacturing, and regulation remain challenges, engineered microbes could become a new platform for precision medicine.",[36,37,38],"p",{},"Imagine taking a medicine that adapts to what is happening inside your body. Instead of swallowing a fixed dose, what if a treatment could enter the gut, recognize a biological signal, perform a specific task, and then disappear?",[36,40,41],{},"That sounds futuristic, but researchers are building medicines that work this way.",[36,43,44],{},"The idea starts with the human microbiome—the enormous community of microorganisms living throughout the body, especially in the gut. Many of these microbes are harmless and beneficial, helping break down food, producing useful molecules, interacting with the immune system, and shaping their environment.",[36,46,47],{},"That makes them interesting to scientists. Could researchers redesign them to do something useful there?",[36,49,50],{},"Advances in synthetic biology have made that increasingly possible. Scientists can modify bacterial DNA and give microbes new instructions, allowing them to sense biological signals, produce therapeutic molecules, or break down disease-associated substances.",[36,52,53],{},"But engineering the bacteria is only half the problem. A living medicine must behave predictably after it enters a person. Scientists need to know whether it will survive, where it will go, how long it will remain active, and whether it can eventually be removed.",[36,55,56],{},"Recent research has begun to address that problem—and the solution involves controlling what the bacteria can eat.",[36,58,59],{},[60,61],"img",{"alt":62,"className":63,"src":65,"style":66},"From natural bacteria to engineered living medicines",[64],"rounded-lg","\u002Fnewsletter\u002Fmicrobiomeeng\u002Ffig1.png","display: block; margin-inline: auto;",[36,68,72],{"className":69},[70,71],"text-sm","text-center","\nFigure 1. From natural bacteria to engineered living medicines. Natural bacteria can be modified through synthetic biology to gain specific therapeutic functions in the gut.\nCreated with BioRender.com.\n",[12,74,76],{"id":75},"from-microbes-to-medicines","From Microbes to Medicines",[36,78,79],{},"The human body is an ecosystem. The gut contains a huge community of bacteria and other microorganisms that constantly interact with one another and with their host. For an engineered bacterium, entering that crowded environment is a challenge: it must compete for nutrients and find a way to establish itself among microbes that are already there. Researchers therefore needed a way to give their engineered bacteria an advantage without permanently changing the entire microbial community.",[36,81,82],{},"Synthetic biology gives researchers a way to change the rules. Scientists can modify a bacterium's genome and add genetic circuits that determine when certain genes turn on or off. A microbe could, for example, be designed to produce a therapeutic molecule only when it encounters a particular biological signal.",[36,84,85],{},"These organisms are sometimes described as engineered live biotherapeutic products or synthetic biotics. Instead of simply delivering a manufactured drug, the microorganism itself carries out a therapeutic function.",[36,87,88,89,93],{},"One early example involved phenylketonuria, or PKU, a genetic disorder in which the body has difficulty processing the amino acid phenylalanine. Researchers engineered ",[90,91,92],"em",{},"Escherichia coli"," Nissle 1917 strains to metabolize phenylalanine in the gut. In a 2023 Phase 2 clinical trial, SYNB1618 and SYNB1934 reduced phenylalanine exposure in PKU patients, demonstrating that engineered microbes could perform specific metabolic functions inside the human body (Vockley et al., 2023).",[36,95,96],{},"That breakthrough raised a fundamental question: What happens when the medicine itself is alive?",[36,98,99],{},"Researchers could engineer bacteria to perform specific tasks, but the harder problem was keeping those bacteria in place, active for the right amount of time, and then removing them. That challenge became the focus of a new generation of microbiome research.",[36,101,102],{},[60,103],{"alt":104,"className":105,"src":106,"style":66},"How an engineered bacterium works inside the body",[64],"\u002Fnewsletter\u002Fmicrobiomeeng\u002Ffig2.png",[36,108,110],{"className":109},[70,71],"\nFigure 2. Engineered bacteria can contain genetic instructions that control when they sense biological signals, activate genetic circuits, and produce therapeutic molecules or perform other functions.\nCreated with BioRender.com.\n",[12,112,114],{"id":113},"the-hard-part-controlling-a-living-medicine","The Hard Part: Controlling a Living Medicine",[36,116,117],{},"Conventional drugs allow researchers to determine dose and duration of action, but an engineered bacterium is different. It is a living organism that interacts with thousands of others and adapts to changing conditions.",[36,119,120],{},"Therefore, researchers needed a biological way to control how long engineered bacteria remained in the body. If a bacterium disappeared too quickly, it might not treat the disease. If it lingered indefinitely, scientists would have less control over the therapy.",[36,122,123],{},"One promising approach came from earlier research on microbial nutrition. Scientists found that engineered bacteria could be given access to a nutrient unavailable to much of the existing gut microbiome. One study used porphyran, a seaweed-derived carbohydrate, to create a nutritional niche for engineered bacteria. Providing the nutrient helped those bacteria establish themselves in the gut even when competing with an existing microbial community (Shepherd et al., 2018).",[36,125,126],{},"This solved one problem—but created another. If the bacteria depended on a specific nutrient to survive, could scientists use that same dependency to control when they remained in the body?",[36,128,129],{},"Researchers began to wonder whether the same nutritional advantage that helped engineered bacteria establish themselves could also give scientists control over how long they stayed. If the bacteria depended on a nutrient that researchers could provide or withhold, access to that nutrient could become a way to regulate the living medicine.",[12,131,133],{"id":132},"a-bacterium-with-an-off-switch","A Bacterium With an Off Switch",[36,135,136,137,140,141,144],{},"In 2025, Weston Whitaker and colleagues reported a major breakthrough in ",[90,138,139],{},"Science",". The researchers built on the earlier porphyran strategy by engineering a strain of ",[90,142,143],{},"Phocaeicola vulgatus"," whose survival depended on porphyran.",[36,146,147],{},"The team altered the regulation of an essential bacterial gene so that it was activated by porphyran. When porphyran was available, the engineered bacteria could maintain the essential function needed for survival. When porphyran was removed, that function could no longer be maintained.",[36,149,150],{},"The researchers were no longer simply trying to make bacteria colonize the gut. They were trying to make colonization controllable.",[36,152,153],{},"The researchers adapted the system into a potential treatment for enteric hyperoxaluria, a condition that can contribute to recurrent calcium oxalate kidney stones. The bacterium was engineered to carry a five-gene pathway that could break down oxalate, creating a microbial system with two key features: it could perform a therapeutic function, and its presence could be regulated through access to porphyran (Whitaker et al., 2025).",[36,155,156],{},[60,157],{"alt":158,"className":159,"src":160,"style":66},"The engineered Phocaeicola vulgatus for oxalate degradation",[64],"\u002Fnewsletter\u002Fmicrobiomeeng\u002Ffig3.png",[36,162,164,165,167],{"className":163},[70,71],"\nFigure 3. The engineered ",[90,166,143],{}," uses a porphyran-dependent system for survival and a five-gene pathway to break down oxalate into degraded products.\nCreated with BioRender.com.\n",[36,169,170],{},"Before testing the approach in people, the researchers studied whether the engineered bacteria could perform their intended function in animal models. The results provided evidence that the bacteria could reduce oxalate levels.",[36,172,173],{},"Then came the tougher test: Could the system be controlled in humans?",[36,175,176],{},"In a Phase 1\u002F2a clinical trial, researchers tested the engineered bacteria in people. The bacteria's abundance increased as porphyran exposure increased, while removing the nutrient reversed engraftment. The study also reported reduced urinary oxalate levels (Whitaker et al., 2025).",[36,178,179],{},"The trial results represented a significant shift in the direction of microbial medicine research. For the first time, researchers demonstrated in humans that they could influence the presence of an engineered therapeutic bacterium by controlling its access to a nutrient. The living medicine was no longer simply being introduced into the body; researchers had a way to influence when it could remain there.",[36,181,182,183,186],{},"A 2025 ",[90,184,185],{},"Nature Biotechnology"," research highlight described the work as a step toward solving a fundamental problem in microbial cell therapy: engineered bacteria must colonize the gut effectively but also be cleared when treatment ends (Marchal, 2025).",[36,188,189],{},"The experiment demonstrated something earlier generations of microbial engineering had struggled to achieve: a living medicine could be designed with a controllable relationship to its environment.",[36,191,192],{},"The question had changed. It was no longer just, \"Can scientists engineer bacteria?\" It was, \"Can scientists engineer bacteria into medicines that can be controlled?\"",[36,194,195],{},"That distinction matters. A treatment that works only in a laboratory is very different from one that can be introduced into a human body, perform a useful function, and then be regulated.",[36,197,198],{},[60,199],{"alt":200,"className":201,"src":202,"style":66},"Controlling a living medicine in the human gut",[64],"\u002Fnewsletter\u002Fmicrobiomeeng\u002Ffig4.png",[36,204,206],{"className":205},[70,71],"\nFigure 4. The 2025 human trial demonstrated that an engineered microbial therapy could perform a therapeutic function while its colonization remained controllable, addressing a major challenge in developing living medicines.\nCreated with BioRender.com.\n",[12,208,210],{"id":209},"where-could-living-medicines-go-next","Where Could Living Medicines Go Next?",[36,212,213],{},"The controlled-colonization study is one example of how researchers are making engineered bacteria more practical. Other teams are exploring what these microbes can do once inside the body.",[36,215,216],{},"Metabolic disorders are one area of interest. In PKU, engineered bacteria have been designed to break down phenylalanine before it contributes to elevated levels in the body (Vockley et al., 2023). Similar strategies could be adapted to other conditions involving molecules that accumulate or need to be modified.",[36,218,219],{},"The gastrointestinal tract is another natural target. Researchers are investigating whether engineered bacteria could detect signals associated with intestinal inflammation and release therapeutic molecules near affected tissue. The goal is to make the microbe respond to its biological environment rather than release the same treatment continuously.",[36,221,222,223,226,227,230],{},"Cancer research is pushing the idea further. In a 2024 ",[90,224,225],{},"Nature"," study, researchers engineered probiotic ",[90,228,229],{},"E. coli"," Nissle 1917 to deliver tumor-specific neoantigens and stimulate an immune response against cancer. In mouse models, the engineered bacteria helped activate tumor-specific immune responses and produced antitumor effects (Redenti et al., 2024). The work remains preclinical, but it demonstrates how bacteria could serve as programmable delivery systems for cancer immunotherapy.",[36,232,233],{},"Across these examples, the same principle keeps appearing: give a microorganism a useful biological job, then build enough control around it to make that job practical.",[36,235,236],{},[60,237],{"alt":238,"className":239,"src":240,"style":66},"Potential applications of engineered microbial therapies",[64],"\u002Fnewsletter\u002Fmicrobiomeeng\u002Ffig5.png",[36,242,244],{"className":243},[70,71],"\nFigure 5. Engineered microbes are being investigated as programmable therapies for metabolic disorders, gastrointestinal diseases, and cancer immunotherapy, demonstrating the range of potential applications for living medicines.\nCreated with BioRender.com.\n",[12,246,248],{"id":247},"what-still-has-to-be-solved","What Still Has to Be Solved?",[36,250,251],{},"Engineered medicines hold promise, but the field is still emerging. Several challenges must be addressed before engineered microbial therapies become routine medical treatments.",[36,253,254],{},"Safety and control are major concerns. Engineered bacteria respond to their environment and interact with existing microbial communities. Researchers need to understand how long these microbes remain active, where they travel, and how their activity can be controlled.",[36,256,257],{},"Genetic stability is another challenge. Engineered bacteria must maintain the traits that make them therapeutic. The 2025 controlled-colonization study also highlighted the need to monitor the movement of engineered genetic material between microorganisms (Whitaker et al., 2025).",[36,259,260],{},"Microbiome interactions add another layer of complexity. The gut contains thousands of microbial species competing and cooperating with one another. A bacterium that behaves predictably in a laboratory may behave differently within a person's existing microbiome.",[36,262,263],{},"Manufacturing poses a practical challenge as well. Researchers must produce microbial therapies consistently, ensuring that each batch has the correct genetic characteristics and therapeutic activity.",[36,265,266],{},"Regulation is also complicated because engineered microbes do not fit neatly into the traditional idea of a drug. They are living organisms that grow, respond to their surroundings, and interact with other organisms inside the body.",[36,268,269],{},"These challenges are significant, but they are also driving the next generation of research. The goal is to make bacteria perform a useful function safely, consistently, and predictably.",[12,271,273],{"id":272},"why-this-matters","Why This Matters",[36,275,276],{},"Engineering the microbiome represents a broader shift in how scientists think about medicine. Instead of treating bacteria as something to eliminate, researchers are learning how to use microorganisms as biological tools.",[36,278,279],{},"The most interesting possibility may be what this means for precision medicine. A traditional drug is manufactured outside the body and delivered to a patient. An engineered microbe could respond to the environment it encounters inside the body, creating possibilities for treatments that are more responsive and localized.",[36,281,282],{},"A bacterium could detect a biological condition, carry out a programmed reaction, and potentially be removed once its job is finished. This would make the treatment less like a passive dose of medicine and more like a biological system designed to respond to the patient's environment.",[36,284,285],{},"Making this vision work requires collaboration across many fields. Microbiologists study how the organisms behave. Geneticists and synthetic biologists design their DNA. Biomedical engineers develop systems for controlling them. Computational scientists analyze microbial communities and biological data. Physicians and clinical researchers determine whether these technologies actually help patients.",[36,287,288],{},"For students interested in biology, medicine, biotechnology, or engineering, microbiome engineering shows how these subjects can overlap in a single problem. The next breakthrough in medicine could come from someone studying bacterial behavior, designing genetic circuits, developing a new control system, analyzing microbiome data, or translating laboratory discoveries into patient care.",[36,290,291],{},[60,292],{"alt":293,"className":294,"src":295,"style":66},"Fields behind engineered living medicines",[64],"\u002Fnewsletter\u002Fmicrobiomeeng\u002Ffig6.png",[36,297,299],{"className":298},[70,71],"\nFigure 6. Developing engineered living medicines requires collaboration across microbiology, genetics and synthetic biology, biomedical engineering, computational science, and clinical research, connecting microbial design with the development and testing of new therapies.\nCreated with BioRender.com.\n",[12,301,303],{"id":302},"conclusion","Conclusion",[36,305,306],{},"The human microbiome was once studied primarily as a community of microorganisms living inside us. Synthetic biology has given researchers a new perspective: an environment where living organisms can be programmed to perform medical tasks.",[36,308,309],{},"Early clinical work showed that engineered bacteria could metabolize phenylalanine in people with PKU (Vockley et al., 2023). More recent research has pushed beyond that. Scientists are now asking how to control where engineered microbes live, how long they remain active, and how to remove them.",[36,311,312],{},"The 2025 controlled-colonization study offered a crucial step toward answering those questions. Researchers linked bacterial survival to a controllable nutrient, demonstrating reversible engraftment of an engineered microbe in humans while testing its therapeutic function (Whitaker et al., 2025). The study also exposed challenges that still need to be solved, particularly genetic stability and interactions between engineered bacteria and the existing microbiome.",[36,314,315],{},"That combination of progress and unanswered questions makes microbiome engineering compelling. Science is no longer just about imagining bacteria as medicines. Researchers are figuring out how to make that idea controllable enough to test in the real world.",[36,317,318],{},"If these challenges can be overcome, engineered microbes could become a new kind of medicine—one that senses, responds, and acts inside the body.",[12,320,322],{"id":321},"references","References",[324,325,326,335,342,349,356],"ol",{},[20,327,328,329],{},"Marchal, I. (2025). Reversible engraftment of an engineered microbe in the human gut. Nature Biotechnology, 43, 1241. ",[330,331,332],"a",{"href":332,"rel":333},"https:\u002F\u002Fdoi.org\u002F10.1038\u002Fs41587-025-02790-x",[334],"nofollow",[20,336,337,338],{},"Redenti, A., Im, J., Redenti, B., Li, F., Rouanne, M., Sheng, Z., Sun, W., Gurbatri, C. R., Huang, S., Komaranchath, M., Jang, Y., Hahn, J., Ballister, E. R., Vincent, R. L., Vardoshivilli, A., Danino, T., & Arpaia, N. (2024). Probiotic neoantigen delivery vectors for precision cancer immunotherapy. Nature, 635, 453–461. ",[330,339,340],{"href":340,"rel":341},"https:\u002F\u002Fdoi.org\u002F10.1038\u002Fs41586-024-08033-4",[334],[20,343,344,345],{},"Shepherd, E. S., DeLoache, W. C., Pruss, K. M., Whitaker, W. R., & Sonnenburg, J. L. (2018). An exclusive metabolic niche enables strain engraftment in the gut microbiota. Nature, 557, 434–438. ",[330,346,347],{"href":347,"rel":348},"https:\u002F\u002Fdoi.org\u002F10.1038\u002Fs41586-018-0092-2",[334],[20,350,351,352],{},"Vockley, J., Sondheimer, N., Puurunen, M., Diaz, G. A., Ginevic, I., Grange, D. K., Harding, C., Northrup, H., Phillips, J. A., Searle, S., Thomas, J. A., Zori, R., Denney, W. S., Ernst, S. L., Humphreys, K., McWhorter, N., Kurtz, C., & Brennan, A. M. (2023). Efficacy and safety of a synthetic biotic for treatment of phenylketonuria: A phase 2 clinical trial. Nature Metabolism, 5, 1685–1690. ",[330,353,354],{"href":354,"rel":355},"https:\u002F\u002Fdoi.org\u002F10.1038\u002Fs42255-023-00897-6",[334],[20,357,358,359],{},"Whitaker, W. R., Russ, Z. N., Shepherd, E. S., Popov, L. M., Louie, A., Lam, K., Zong, D. M., Gill, C. C. C., Gehrig, J. L., Rishi, H. S., Tan, J. A., Buness, A., Godoy, J., Banta, D., Jaidka, S., Wilson, K., Flood, J., Bukshpun, P., Yocum, R., Cook, D. N., Warsi, T., McLean, L., Sonnenburg, J. L., & DeLoache, W. C. (2025). Controlled colonization of the human gut with a genetically engineered microbial therapeutic. Science, 389(6757), 303–308. ",[330,360,361],{"href":361,"rel":362},"https:\u002F\u002Fdoi.org\u002F10.1126\u002Fscience.adu8000",[334],{"title":364,"searchDepth":365,"depth":365,"links":366},"",2,[367,368,369,370,371,372,373,374,375],{"id":14,"depth":365,"text":15},{"id":75,"depth":365,"text":76},{"id":113,"depth":365,"text":114},{"id":132,"depth":365,"text":133},{"id":209,"depth":365,"text":210},{"id":247,"depth":365,"text":248},{"id":272,"depth":365,"text":273},{"id":302,"depth":365,"text":303},{"id":321,"depth":365,"text":322},"2026-08-15","Scientists are redesigning gut bacteria to sense biological signals, break down harmful molecules, and produce therapeutic substances inside the body — and a 2025 trial showed these living medicines can be switched off.","md",{"image":65},true,"\u002Fnewsletter\u002Fmicrobiomeeng",{"title":6,"description":377},"newsletter\u002Fmicrobiomeeng","euywGTFAjLrJuKO7yTOdxFPAx-os2_og-bAv1d15hnc",{"id":386,"title":387,"author":388,"body":389,"date":531,"description":532,"extension":378,"meta":533,"navigation":380,"path":534,"seo":535,"stem":536,"__hash__":537},"newsletter\u002Fnewsletter\u002Fnonoppain.md","The Rise of Non-Opioid Pain Relief","Shereen Ali",{"type":9,"value":390,"toc":521},[391,393,410,414,417,420,427,431,434,437,441,444,447,456,464,466,469,472,478,484,492,495,498,501,504,507,510,518],[12,392,15],{"id":14},[17,394,395,398,401,404,407],{},[20,396,397],{},"Opioids’ high potential for addiction and abuse has led to strict legal institutional controls",[20,399,400],{},"Non-opioid painkillers are designed to relieve severe pain without the risks of addiction",[20,402,403],{},"Categorizing pain ensures the precise selection of targeted first-line non-opioids",[20,405,406],{},"Newer medications selectively inhibit Nav1.8 sodium channels on peripheral sensory neurons",[20,408,409],{},"Non-opioids target the peripheral nervous system (PNS) to block or reduce pain signals at their origin before they reach the brain",[12,411,413],{"id":412},"introduction","Introduction",[36,415,416],{},"The pain is sharp and constant, your body aching from every incision. After major surgery, waking up in a hospital bed while still feeling the effects of anesthesia leaves you wanting only one thing: relief. Yet when you arrive at the pharmacy to fill your prescription, you are told that the opioid painkiller your doctor ordered cannot be fully dispensed—regulatory restrictions and limited inventory stand between you and the medication you need. This scenario is not uncommon. Opioids such as morphine and oxycodone remain among the most effective treatments for post-surgical pain, but their high potential for addiction and abuse has led to strict legal institutional controls that often leave patients without adequate access, even in moments of legitimate medical need.",[36,418,419],{},"There is an emerging solution to this dilemma: non-opioid surgical painkillers, a class of treatments designed to relieve severe pain without the risks of addiction. If successfully developed and implemented, these alternatives could transform patient care by eliminating the risk of abuse, reducing dangerous side effects, and preventing the onset of chronic pain, all of which enables faster, more complete recovery. Understanding the clinical potential of these non-opioid options is essential not only for improving the individual patient outcomes, but for reshaping how the healthcare industry approaches pain management as a whole.",[36,421,422],{},[60,423],{"alt":424,"className":425,"src":426,"style":66},"Diagram explaining what pain is",[64],"\u002Fnewsletter\u002Fnonoppain\u002Fwhat.png",[12,428,430],{"id":429},"current-state","Current State",[36,432,433],{},"Diagnostic measures for non-opioid pain management rely on clinical evaluation, validated scoring tools, and mechanism-specific testing. This process categorizes pain as nociceptive, inflammatory, or neuropathic. Identifying these mechanisms ensures the precise selection of targeted first-line non-opioids, such as NSAIDs, acetaminophen, or specific adjuvant medications.",[36,435,436],{},"Nociceptive pain is assessed through localized tenderness and functional limitation, fit for acetaminophen or short-term anti-inflammatory therapy. Ibuprofen, naproxen, celecoxib, and meloxicam reduce inflammation and pain. They are first-line agents for musculoskeletal pain, postoperative pain, and inflammatory conditions (American Academy). Furthermore, neuropathic pain is diagnosed via sensory testing and clinical scoring tools (e.g., LANSS or DN4) for conditions like diabetic neuropathy or postherpetic neuralgia, targeting antiepileptic drugs (Zero). Lastly, inflammatory pain is diagnosed via physical examination, imaging (X-ray\u002FMRI), or inflammatory marks confirming conditions like osteoarthritis or acute injury, matching target patients to oral or topical NSAIDs. This identification of patient categories and matching measures ensures patients receive highly effective, tailored pain management by directly aligning specific pain mechanisms with the safest and most appropriate non-opioid medications.",[12,438,440],{"id":439},"sodium-channels-pns","Sodium Channels & PNS",[36,442,443],{},"Sodium channels are a diverse family of isoform proteins with unique expression patterns and functions. They are located in the cell membrane of excitable and absorptive cells throughout the body, specifically concentrated in neurons, muscle cells, and epithelial tissues. The targeting of a single isoform can alter pain sensations. Thus, these channels play a role in the maintenance of inflammatory pain states (Levinson). Consequently, selectively blocking these specific channels offers a promising pathway for developing effective non-opioid painkillers without the risk of addiction.",[36,445,446],{},"Non-opioid painkillers like NSAIDs directly target inflammatory pain states. They block cyclooxygenase (COX) enzymes, stopping the body from making prostaglandins—the chemical signals that cause tissue swelling, redness, and sensitize pain nerves. This makes non-opioids the primary, most effective first-line treatment for mild-to-moderate inflammatory conditions (Milani).",[36,448,449,450,455],{},"Additionally, sodium channel subtypes are crucial for understanding the mechanism of non-opioid painkillers. For example, Nav1.8 is a voltage-gated sodium channel protein encoded by the SCN10A gene that plays a critical role in transmitting pain signals. It is found mainly in the sensory neurons of the peripheral nervous system (PNS), making it a major target for developing non-addictive, non-opioid pain medications.\n",[60,451],{"alt":452,"className":453,"src":454,"style":66},"Diagram showing the CNS and PNS",[64],"\u002Fnewsletter\u002Fnonoppain\u002Fcns.png","\nEssentially, these voltage-gated sodium channels in the peripheral nervous system act as electrical switches that generate and transmit pain signals from injured tissue to the brain. Because these channels exist exclusively outside the brain and spinal cord, the drugs work entirely in the peripheral nervous system (Wiegmann).",[36,457,458,459],{},"Modern non-opioid surgical painkillers, such as the selective Nav1.8 inhibitor suzetrigine (Journavx), block these specific peripheral channels to stop pain messages before they reach the central nervous system, avoiding addiction risks. The drug binds specifically to the voltage-sensing domain 2 of the NaV1.8 channel, locking it in a closed state to prevent the influx of sodium ions. This action blocks the generation of action potentials in pain-sensing neurons, stopping the transmission of pain signals at the source without causing central nervous system side effects like sedation.\n",[60,460],{"alt":461,"className":462,"src":463,"style":66},"Diagram showing the Nav 1.8 channel that non-opioid medications operate on",[64],"\u002Fnewsletter\u002Fnonoppain\u002Fdiag.png",[12,465,303],{"id":302},[36,467,468],{},"Ultimately, non-opioid pain killer research has accelerated rapidly, focusing on highly targeted alternatives like peripheral sodium channel blockers and advanced multimodal therapies. Driven by the urgent medical need to bypass regulatory hurdles and dependency risks, the global market for these non-addictive treatments is predicted to grow exponentially over the coming decade. Fundamentally, these innovations promise a future where surgical recovery is defined by effective, unhindered relief rather than the complications of supply shortages and addiction.",[470,471],"hr",{},[473,474,477],"h3",{"className":475,"id":476},[71],"works-cited","Works Cited",[470,479],{"className":480},[481,482,483],"border-cyan-700","mx-auto","max-w-[80cqw]",[36,485,486,487,491],{},"American Academy of Procedural Medicine. “Pain Management without Opioids: 12 Evidence-Based Approaches.” AAOPM - American Academy of Procedural Medicine, American Academy of Procedural Medicine, 21 Mar. 2026, ",[330,488,489],{"href":489,"rel":490},"https:\u002F\u002Faaopm.com\u002Fblog\u002Fpain-management-without-opioids\u002F#non-opioid-medications",[334],". Accessed 17 July 2026.",[36,493,494],{},"Cleveland Clinic. “Peripheral Nervous System (PNS): What It Is & Function.” Cleveland Clinic, 25 May 2022.",[36,496,497],{},"Hernandez, Carlos M., and John R. Richards. “Physiology, Sodium Channels.” StatPearls Publishing, 2021.",[36,499,500],{},"Levinson, Simon R et al. “The role of sodium channels in chronic pain.” Muscle & nerve vol. 46,2 (2012): 155-65. doi:10.1002\u002Fmus.23314",[36,502,503],{},"Milani, Daniel A. Queremel , and Donald D. Davis. “Pain Management Medications.” StatPearls Publishing, 2023.",[36,505,506],{},"Wiegmann, Aaron L et al. “Suzetrigine: What Should Plastic Surgeons Know?.” Plastic and reconstructive surgery. Global open vol. 14,1 e7431. 16 Jan. 2026, doi:10.1097\u002FGOX.0000000000007431",[36,508,509],{},"Woolf, Clifford J. “What is this thing called pain?.” The Journal of clinical investigation vol. 120,11 (2010): 3742-4. doi:10.1172\u002FJCI45178",[36,511,512,513,517],{},"Wu, Zhixing, and Dai Lu. “Advances in the Discovery of Selective NaV1.8 Inhibitors for Pain Management.” European Journal of Medicinal Chemistry, vol. 302, 30 Oct. 2025, p. 118326, ",[330,514,515],{"href":515,"rel":516},"https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002FS0223523425010918",[334],", 10.1016\u002Fj.ejmech.2025.118326. Accessed 1 Aug. 2026.",[36,519,520],{},"Zero To Finals. “Understanding the Causes of Pain and Pain Management.” 10 Oct. 2022.",{"title":364,"searchDepth":365,"depth":365,"links":522},[523,524,525,526,527],{"id":14,"depth":365,"text":15},{"id":412,"depth":365,"text":413},{"id":429,"depth":365,"text":430},{"id":439,"depth":365,"text":440},{"id":302,"depth":365,"text":303,"children":528},[529],{"id":476,"depth":530,"text":477},3,"2026-08-10","Opioids are highly dangerous and addictive, but are still used for pain relief. Non-opioid painkillers are being designed to overcome the risks of addiction.",{"image":463},"\u002Fnewsletter\u002Fnonoppain",{"title":387,"description":532},"newsletter\u002Fnonoppain","vDEMN3Xd1_HsHB7M0SdBnefkqByo66NsQw-kvJkW-PQ",{"id":539,"title":540,"author":7,"body":541,"date":863,"description":864,"extension":378,"meta":865,"navigation":380,"path":866,"seo":867,"stem":868,"__hash__":869},"newsletter\u002Fnewsletter\u002Fperscancvacc.md","Personalized Cancer Vaccines",{"type":9,"value":542,"toc":853},[543,545,562,565,568,571,578,582,585,588,591,598,602,606,609,612,615,618,621,624,631,635,639,642,645,652,656,659,662,665,669,672,675,678,681,684,687,690,693,696,699,702,705,712,716,720,723,726,729,732,736,739,742,745,748,751,754,756,759,762,765,767],[12,544,15],{"id":14},[17,546,547,550,553,556,559],{},[20,548,549],{},"Every person’s cancer carries a different combination of genetic mutations, giving each tumor its own set of possible immune targets.",[20,551,552],{},"Personalized cancer vaccines use information from a patient’s tumor to train the immune system to recognize and attack that specific cancer.",[20,554,555],{},"Advances in genetic sequencing, computer-based tumor analysis, and mRNA technology have made these individualized treatments faster and more practical to develop.",[20,557,558],{},"Clinical trials are testing personalized cancer vaccines across multiple cancer types, with researchers investigating how these treatments can improve cancer care.",[20,560,561],{},"Larger trials are still underway, but personalized cancer vaccines could help move cancer care toward treatments designed around each patient’s unique biology.",[36,563,564],{},"Imagine being told that your next vaccine was designed for only one person—you. Scientists would analyze the genetic information in your tumor, identify features that separate your cancer cells from healthy cells, and use those findings to build a treatment specifically for your body. Unlike the vaccines most people receive to prevent infections, this vaccine would be given after cancer develops. Its goal would be to help your immune system recognize the cancer and fight it more effectively.",[36,566,567],{},"Cancer has traditionally been treated with surgery, chemotherapy, radiation therapy, and immunotherapy. These treatments have improved outcomes for many patients, but cancer does not look exactly the same in every person. Even two patients diagnosed with the same type of cancer can have tumors driven by different genetic mutations. A treatment that works well for one patient may therefore be less effective for another.",[36,569,570],{},"As a tumor develops, mutations can cause cancer cells to produce unusual proteins that differ from those found in healthy cells. These proteins act as potential targets for the immune system to recognize and bind to. This idea is the foundation of personalized cancer vaccines. Because these proteins vary from patient to patient, a single vaccine is unlikely to recognize every person's cancer equally well. Personalized cancer vaccines solve this problem by using information from an individual tumor to identify the best targets for that patient's immune system.",[36,572,573],{},[60,574],{"alt":575,"className":576,"src":577,"style":66},"Process of Neoantigens attaching to create personalized targets",[64],"\u002Fnewsletter\u002Fperscancvacc\u002Fprocess.png",[36,579,581],{"className":580},[71,70],"Figure 1. Genetic mutations in tumor cells create unique neoantigens that serve as the personalized targets used to design individualized cancer vaccines.\nCreated with BioRender.com.",[36,583,584],{},"Until recently, creating a separate vaccine for every patient was difficult to imagine on a practical scale. Today, faster DNA sequencing, improved computer analysis, and advances in mRNA technology have made it possible to design individualized vaccines much more quickly than before. These treatments are still experimental, but the field is progressing rapidly. Researchers are now testing personalized cancer vaccines in clinical trials across several cancer types. Although these treatments are still experimental, early results have shown that individualized vaccines can be created and safely evaluated in patients. Larger trials are still needed to determine how effective these treatments will be across broader populations.",[36,586,587],{},"This technology could also provide another line of defense against cancer cells left behind for patients who have already undergone surgery, helping to reduce the likelihood that cancer will return.",[36,589,590],{},"Recent advances in personalized mRNA cancer vaccines show how scientists are beginning to turn precision oncology from an idea into a practical treatment, designing therapies around each patient's unique biology while producing them quickly enough to make a clinical difference.",[36,592,593],{},[60,594],{"alt":595,"className":596,"src":597,"style":66},"Comparison between traditional and personalized treatment",[64],"\u002Fnewsletter\u002Fperscancvacc\u002Fcompare.png",[36,599,601],{"className":600},[71,70],"Figure 2. Traditional cancer treatments use standardized therapies, while personalized cancer vaccines are designed around the unique genetic features of each patient's tumor.\nCreated with BioRender.com.\n",[12,603,605],{"id":604},"why-every-tumor-is-different","Why Every Tumor Is Different",[36,607,608],{},"No two cancers follow exactly the same path. Cancer begins when DNA inside a cell gradually accumulates mutations—changes in the genetic instructions that tell cells how to grow, divide, and function. Some of these mutations have little effect, but others allow cells to multiply uncontrollably, avoid normal repair systems, and eventually form a tumor. Because mutations build up over time in different ways, every person's cancer develops its own unique genetic fingerprint.",[36,610,611],{},"Those mutations do more than change how cancer behaves. They can also cause cancer cells to produce abnormal proteins that healthy cells do not make. When these proteins are broken down, small fragments called neoantigens appear on the surface of cancer cells. You can think of neoantigens as tiny identification tags that signal something about the cell is different, giving the immune system a chance to recognize it as abnormal. As shown in Figure 3, these neoantigens can become targets for T cells.",[36,613,614],{},"The challenge is that each patient's collection of neoantigens is different. A melanoma in one patient may display hundreds of neoantigens that are completely different from those found in another person's melanoma. Even patients diagnosed with the same cancer type can have tumors with very different mutation patterns. As a result, a vaccine designed for one person's cancer would likely miss the targets found in someone else's.",[36,616,617],{},"This realization changed how scientists thought about therapeutic cancer vaccines. Earlier approaches often targeted proteins that many tumors shared, hoping a single vaccine could work for large groups of patients. While those strategies improved researchers' understanding of cancer immunotherapy, they produced limited success because they could not account for the extraordinary genetic diversity found from one tumor to another.",[36,619,620],{},"Personalized cancer vaccines take a different approach. Instead of searching for one target that every patient shares, researchers begin with the patient's own tumor. After sequencing the tumor's DNA, they identify the neoantigens most likely to trigger an immune response and use that information to create an individualized vaccine. In other words, the treatment is built around the biology of the patient rather than expecting the patient to fit the treatment.",[36,622,623],{},"Recognizing that every tumor is genetically unique answered one important question: why a universal cancer vaccine was unlikely to succeed. It also raised a far more difficult one. Could scientists identify those unique neoantigens, manufacture a personalized vaccine within weeks, and deliver it in time to help patients before their cancer returned? That question has driven some of the most significant advances in cancer immunotherapy over the past few years and set the stage for the breakthroughs now transforming cancer treatment.",[36,625,626],{},[60,627],{"alt":628,"className":629,"src":630,"style":66},"Process of recognization",[64],"\u002Fnewsletter\u002Fperscancvacc\u002Fimmune.png",[36,632,634],{"className":633},[71,70],"Figure 3. Each tumor's unique neoantigens allow T cells to recognize cancer cells, forming the biological foundation of personalized cancer vaccines.\nCreated with BioRender.com.\n",[12,636,638],{"id":637},"current-state-of-personalized-cancer-vaccines-20242026","Current State of Personalized Cancer Vaccines (2024–2026)",[36,640,641],{},"Just a few years ago, designing a personalized cancer vaccine for every patient sounded more like a long-term goal than a realistic treatment strategy. Today, the field looks very different. Advances in DNA sequencing, computational biology, and mRNA technology have made it possible for researchers to develop individualized vaccines quickly enough to test them in clinical trials, transforming personalized cancer vaccines into one of the most rapidly advancing areas of precision oncology.",[36,643,644],{},"Once a patient's tumor is removed or biopsied, the race to create a personalized vaccine begins. Scientists sequence the tumor's DNA and compare it with healthy cells to pinpoint the mutations unique to that cancer. Computer algorithms then analyze thousands of possible neoantigens, identifying those most likely to trigger a strong immune response. Using that information, researchers design an individualized mRNA vaccine that teaches the immune system what to recognize if cancer cells remain in the body. Every step must happen quickly enough for the vaccine to be ready before the patient's cancer has a chance to return. As shown in Figure 4, speed is essential because tumor analysis, target selection, vaccine production, and treatment must all be completed within a limited clinical window.",[36,646,647],{},[60,648],{"alt":649,"className":650,"src":651,"style":66},"Typical schedule of a patient",[64],"\u002Fnewsletter\u002Fperscancvacc\u002Fschedule.png",[36,653,655],{"className":654},[71,70],"Figure 4. Developing a personalized mRNA cancer vaccine requires rapid tumor sequencing, neoantigen selection, vaccine manufacturing, and treatment within a limited clinical window.\nAdapted from Rojas et al. (2023).\n",[36,657,658],{},"Researchers can now complete each of these steps far more efficiently than they could just a few years ago. Personalized vaccines are being studied alongside established immunotherapies, including immune checkpoint inhibitors such as pembrolizumab, because the two approaches may complement one another. While the vaccine teaches the immune system what to recognize, immunotherapy helps remove some of the biological \"brakes\" that can prevent immune cells from attacking tumors. Together, these treatments are being evaluated in clinical trials involving melanoma, pancreatic cancer, glioblastoma, and several other cancer types.",[36,660,661],{},"Despite this rapid progress, important challenges remain. Every vaccine must still be designed and manufactured for a single patient, making the process more complex and expensive than producing a standard treatment. Researchers also continue to refine how neoantigens are selected, shorten manufacturing times, and determine which patients are most likely to benefit. Most importantly, although several early studies have reported encouraging results, larger Phase III clinical trials are still needed before personalized cancer vaccines can become part of routine cancer care.",[36,663,664],{},"Even with these challenges, the field has reached an important turning point. Scientists have shown that personalized vaccines can be created, safely delivered, and tested in patients. The next challenge was determining whether this approach could improve patient outcomes in a large clinical trial. Among these developments, one clinical trial became a major milestone in showing what personalized cancer vaccines could accomplish.",[12,666,668],{"id":667},"breakthrough-story-the-keynote-942-trial","Breakthrough Story: The KEYNOTE-942 Trial",[36,670,671],{},"By the late 2010s, scientists had already reached an important conclusion: every patient's cancer was different. Sequencing technologies had revealed that tumors carried unique combinations of mutations, and researchers knew those mutations could produce neoantigens capable of attracting the immune system's attention. The biology made sense. The problem was turning that idea into a treatment.",[36,673,674],{},"Imagine trying to develop a brand-new treatment for every single patient. Every patient presented researchers with a completely new puzzle. Before treatment could even begin, they had to collect the tumor, decode its DNA, determine which mutations were most likely to alert the immune system, manufacture an entirely new vaccine, and complete safety testing—all within a matter of weeks. Meanwhile, the possibility that the patient's cancer could return meant there was little time to waste.",[36,676,677],{},"That challenge shaped the next generation of cancer vaccine research. To solve it, researchers first had to rethink how cancer vaccines were designed.",[36,679,680],{},"Earlier therapeutic cancer vaccines often targeted proteins shared by many patients, with the hope that a single vaccine could treat large groups of people. Although these studies helped researchers better understand cancer immunotherapy, the results were often limited because tumors varied so much from one patient to another. Scientists began asking a new question: instead of searching for one vaccine that fit everyone, what if every patient received a vaccine built specifically for their own cancer?",[36,682,683],{},"Answering that question required several scientific breakthroughs to come together at the same time.",[36,685,686],{},"The first was rapid genomic sequencing. Improvements in sequencing technology allowed researchers to identify thousands of mutations within an individual's tumor much faster than before. At the same time, advances in computational biology made it possible to analyze enormous amounts of genetic data and predict which neoantigens were most likely to produce a strong immune response. Instead of relying solely on laboratory experiments, researchers could now use sophisticated algorithms to narrow down the best vaccine targets.",[36,688,689],{},"The second breakthrough came from mRNA technology. During the COVID-19 pandemic, mRNA vaccines demonstrated that genetic instructions could be produced quickly and delivered safely to train the immune system. Cancer researchers realized they could adapt the same platform for a completely different purpose. Rather than encoding part of a virus, an mRNA cancer vaccine could encode neoantigens unique to one patient's tumor, allowing the immune system to recognize cancer cells that carried those mutations.",[36,691,692],{},"These advances laid the foundation for the KEYNOTE-942 clinical trial.",[36,694,695],{},"The study enrolled patients with high-risk stage III and stage IV melanoma whose tumors had been completely removed through surgery but still carried a substantial risk of recurring. For each participant, researchers developed an individualized mRNA vaccine, known as mRNA-4157 (V940), by sequencing the patient's tumor and selecting up to 34 neoantigens predicted to generate the strongest immune response. The vaccine was then given alongside pembrolizumab, an immune checkpoint inhibitor already used to treat melanoma. The researchers hoped the combination would not only teach the immune system what to attack but also help immune cells respond more effectively once they recognized those targets.",[36,697,698],{},"The results drew international attention. According to Weber et al. (2024), the Phase IIb trial showed that patients receiving the personalized vaccine together with pembrolizumab had a lower risk of cancer recurrence or death than patients receiving pembrolizumab alone. Follow-up results reported in 2026 showed that this benefit remained durable after five years, strengthening confidence that individualized mRNA vaccines could provide lasting protection for some patients after surgery. At the same time, researchers emphasized that a larger Phase III trial is still underway to determine whether these findings can be confirmed in a broader population.",[36,700,701],{},"The significance of the trial extends beyond melanoma. For decades, personalized cancer vaccines remained largely theoretical because researchers lacked the technology to create them quickly enough for clinical use. KEYNOTE-942 demonstrated that scientists could sequence a patient's tumor, design a unique vaccine, manufacture it within the limited treatment window, and combine it successfully with an existing immunotherapy. It did not prove that personalized cancer vaccines are ready to replace current cancer treatments. It did, however, provide some of the strongest clinical evidence to date that individualized vaccines can become a practical part of precision oncology.",[36,703,704],{},"Perhaps the greatest achievement wasn't a number reported in the study at all. It was showing that a treatment designed for one patient—and one patient alone—could be developed on a timeline fast enough to be tested in real-world cancer care. That accomplishment has helped shape a new direction for cancer research, one in which therapies are increasingly designed around the biology of the individual instead of the average patient.",[36,706,707],{},[60,708],{"alt":709,"className":710,"src":711,"style":66},"Results of the KEYNOTE-942 study",[64],"\u002Fnewsletter\u002Fperscancvacc\u002Fresults.png",[36,713,715],{"className":714},[70,71],"Figure 5. Patients who developed stronger vaccine-induced T-cell immune responses remained cancer-free for longer, illustrating how personalized cancer vaccines may help reduce the risk of cancer recurrence.\nAdapted from Rojas et al. (2023).\n",[12,717,719],{"id":718},"remaining-challenges","Remaining Challenges",[36,721,722],{},"The success of the KEYNOTE-942 trial marks an important step forward, but personalized cancer vaccines are still in the early stages of clinical development. Before these treatments can become part of routine cancer care, researchers must overcome challenges that are specific to designing a separate therapy for each patient.",[36,724,725],{},"One of the greatest obstacles is the complexity of personalized vaccine production. Unlike traditional vaccines, which are manufactured in large batches, each personalized cancer vaccine must be created for an individual patient. Scientists must sequence the tumor’s DNA, identify the most promising neoantigens, design the vaccine, and complete quality testing before treatment can begin. Although advances in technology have made this process much faster, researchers must continue improving manufacturing speed and efficiency to ensure vaccines can be produced within a clinically useful timeframe.",[36,727,728],{},"Another major challenge is determining how well these treatments will work across larger and more diverse patient populations. While studies such as KEYNOTE-942 have shown encouraging results, larger Phase III clinical trials are still needed to confirm whether personalized cancer vaccines consistently improve outcomes. These studies will also help researchers identify which patients are most likely to benefit and how these vaccines can best be combined with other cancer therapies.",[36,730,731],{},"These challenges are significant, but they are also the focus of ongoing research. Scientists have demonstrated that personalized cancer vaccines can be created and tested in clinical settings. The next step is making these treatments faster, more accessible, and reliable enough to become a routine part of cancer care.",[12,733,735],{"id":734},"why-this-matters-future-implications-and-career-connections","Why This Matters: Future Implications and Career Connections",[36,737,738],{},"Personalized cancer vaccines represent a much larger shift in medicine than the development of a single new treatment. For decades, many cancer therapies were designed to treat groups of patients with the same diagnosis. Today, researchers are moving toward precision oncology—an approach that uses a\npatient's own genetic information to guide treatment decisions. Instead of asking, \"What works for this type of cancer?\" researchers are increasingly asking, \"What will work best for this individual patient?\"",[36,740,741],{},"If this approach continues to succeed, the impact could extend far beyond melanoma. Researchers are already studying personalized vaccines for pancreatic cancer, glioblastoma, colorectal cancer, and several other cancers. At the same time, scientists are exploring new ways to improve every step of the process. More accurate neoantigen prediction, artificial intelligence-assisted vaccine design, faster manufacturing methods, and combinations with emerging immunotherapies could make personalized treatments more effective and available to more patients in the future.",[36,743,744],{},"The potential healthcare impact is significant. Treatments designed around a patient's unique tumor may improve outcomes while reducing unnecessary therapies that are less likely to be effective. Although personalized cancer vaccines are unlikely to replace surgery, chemotherapy, radiation therapy, or immunotherapy, they may become an important addition to these treatments by helping the immune system recognize and eliminate cancer cells that remain after initial therapy.",[36,746,747],{},"This research is also creating opportunities for people interested in science and medicine. Developing a personalized cancer vaccine requires experts from many different fields working together. Molecular biologists investigate the genetic mutations within tumors, bioinformaticians and computer scientists develop algorithms to identify the most promising neoantigens, immunologists study how immune cells recognize cancer, and biomedical engineers work to improve vaccine manufacturing. Clinical researchers then evaluate these treatments in carefully designed trials. Progress depends on all of these disciplines working together toward the same goal.",[36,749,750],{},"If you enjoy biology, computer science, engineering, chemistry, or medicine, personalized cancer vaccines demonstrate how those subjects can intersect to solve real healthcare problems. A student interested in coding might one day develop algorithms that identify neoantigens more accurately. Someone fascinated by biology could study how immune cells recognize cancer. An aspiring physician might eventually use personalized vaccines as part of a patient's treatment plan. Advances like these show that scientific breakthroughs rarely come from one discipline—they emerge when researchers with different expertise work toward the same goal.",[36,752,753],{},"Ultimately, personalized cancer vaccines demonstrate how genetics, computational biology, immunology, and biotechnology are converging to reshape modern medicine. While important challenges remain, the progress made over the past few years suggests that future cancer treatments may become increasingly tailored to the biology of each individual patient. What once seemed like a distant possibility is steadily becoming a reality in precision oncology.",[12,755,303],{"id":302},[36,757,758],{},"Not long ago, the idea of creating a different cancer vaccine for every patient seemed unrealistic. Scientists understood that every tumor carried its own unique genetic mutations, but identifying those mutations, designing an individualized treatment, and producing it quickly enough for patients remained beyond the limits of available technology. Advances in genomic sequencing, computational biology, and mRNA technology have changed that. As these fields converged, researchers gained the tools needed to transform a scientific concept into a treatment that could be tested in patients.",[36,760,761],{},"The KEYNOTE-942 clinical trial represents one of the clearest examples of that progress. Rather than relying on a one-size-fits-all approach, researchers demonstrated that an mRNA vaccine could be designed around the biology of an individual patient's tumor and successfully combined with immunotherapy in a clinical setting. While larger Phase III trials are still needed to confirm these results across broader patient populations, the trial has provided some of the strongest evidence to date that personalized cancer vaccines can become a practical part of precision oncology.",[36,763,764],{},"Personalized cancer vaccines are not a cure, and important scientific and logistical challenges still lie ahead. Even so, they offer a glimpse of how medicine is changing—from treating diseases with standardized therapies to designing treatments around each patient's unique biology. As research continues to advance, today's experimental vaccines may become tomorrow's standard of care.",[12,766,322],{"id":321},[324,768,769,776,783,790,797,804,811,818,825,832,839,846],{},[20,770,771,772],{},"American Association for Cancer Research (AACR). (2024). Personalized neoantigen vaccines boost progress against aggressive cancers. ",[330,773,774],{"href":774,"rel":775},"https:\u002F\u002Fwww.aacr.org\u002Fblog\u002F2024\u002F04\u002F10\u002Fpersonalized-neoantigen-vaccines-boost-progress-against-aggressive-cancers\u002F",[334],[20,777,778,779],{},"ClinicalTrials.gov. (2026). A study of mRNA-4157\u002FV940 in combination with pembrolizumab in participants with high-risk melanoma (NCT03897881). ",[330,780,781],{"href":781,"rel":782},"https:\u002F\u002Fclinicaltrials.gov\u002Fstudy\u002FNCT03897881",[334],[20,784,785,786],{},"Genome Medicine. (2024). Neoantigen DNA vaccines are safe, feasible, and induce neoantigen-specific immune responses in triple-negative breast cancer patients. ",[330,787,788],{"href":788,"rel":789},"https:\u002F\u002Flink.springer.com\u002Farticle\u002F10.1186\u002Fs13073-024-01388-3",[334],[20,791,792,793],{},"Journal of Clinical Oncology. (2024). Individualized neoantigen therapy mRNA-4157 (V940) plus pembrolizumab in resected melanoma: 3-year update from the mRNA-4157-P201\u002FKEYNOTE-942 trial. ",[330,794,795],{"href":795,"rel":796},"https:\u002F\u002Fdoi.org\u002F10.1200\u002FJCO.2024.42.17_suppl.LBA9512",[334],[20,798,799,800],{},"MIT Technology Review. (2024). Cancer vaccines are having a renaissance. ",[330,801,802],{"href":802,"rel":803},"https:\u002F\u002Fwww.technologyreview.com\u002F2024\u002F05\u002F03\u002F1092026\u002Fcancer-vaccines-are-having-a-renaissance\u002F",[334],[20,805,806,807],{},"National Cancer Institute. (2019). Cancer vaccines. ",[330,808,809],{"href":809,"rel":810},"https:\u002F\u002Fwww.cancer.gov\u002Fabout-cancer\u002Ftreatment\u002Ftypes\u002Fimmunotherapy\u002Fcancer-vaccines",[334],[20,812,813,814],{},"Nature Communications. (2024). A real-world observation of patients with glioblastoma treated with a personalized peptide vaccine. ",[330,815,816],{"href":816,"rel":817},"https:\u002F\u002Fwww.nature.com\u002Farticles\u002Fs41467-024-51315-8",[334],[20,819,820,821],{},"Nature News. (2024). How personalized cancer vaccines could keep tumours from coming back. ",[330,822,823],{"href":823,"rel":824},"https:\u002F\u002Fdoi.org\u002F10.1038\u002Fd41586-024-01717-x",[334],[20,826,827,828],{},"Nature Reviews Clinical Oncology. (2024). Cancer mRNA vaccines: Clinical advances and future opportunities. ",[330,829,830],{"href":830,"rel":831},"https:\u002F\u002Fwww.nature.com\u002Farticles\u002Fs41571-024-00902-1",[334],[20,833,834,835],{},"Rojas, L. A., Sethna, Z., Soares, K. C., Olcese, C., Pang, N., Patterson, E., et al. (2023). Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Nature. ",[330,836,837],{"href":837,"rel":838},"https:\u002F\u002Fpmc.ncbi.nlm.nih.gov\u002Farticles\u002FPMC10171177\u002F",[334],[20,840,841,842],{},"Science. (2024). Progress on RNA-based cancer vaccines. ",[330,843,844],{"href":844,"rel":845},"https:\u002F\u002Fwww.science.org\u002Fcontent\u002Fblog-post\u002Fprogress-rna-based-cancer-vaccines",[334],[20,847,848,849],{},"Weber, J. S., Carlino, M. S., Khattak, A., Meniawy, T., Ansstas, G., Taylor, M. H., et al. (2024). Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): A randomised, phase 2b study. The Lancet. ",[330,850,851],{"href":851,"rel":852},"https:\u002F\u002Fwww.thelancet.com\u002Fjournals\u002Flancet\u002Farticle\u002FPIIS0140-6736(23)02268-7\u002Fabstract",[334],{"title":364,"searchDepth":365,"depth":365,"links":854},[855,856,857,858,859,860,861,862],{"id":14,"depth":365,"text":15},{"id":604,"depth":365,"text":605},{"id":637,"depth":365,"text":638},{"id":667,"depth":365,"text":668},{"id":718,"depth":365,"text":719},{"id":734,"depth":365,"text":735},{"id":302,"depth":365,"text":303},{"id":321,"depth":365,"text":322},"2026-08-02","Cancer is rapidly changing and evolving, and differs between every patient. Using specific information from patient tumors, personalized vaccines can be developed to help combat the patient's specific cancer more effectively",{"image":577},"\u002Fnewsletter\u002Fperscancvacc",{"title":540,"description":864},"newsletter\u002Fperscancvacc","NOCuE4WzitGSq5D6El2zpEtChvn5Hye7YST-1xqG1NM",{"id":871,"title":872,"author":7,"body":873,"date":1145,"description":1146,"extension":378,"meta":1147,"navigation":380,"path":1148,"seo":1149,"stem":1150,"__hash__":1151},"newsletter\u002Fnewsletter\u002Flaborgans.md","Lab-Grown Organs and Bioengineered Tissue: Advances Toward Transplantable Artificial Organs",{"type":9,"value":874,"toc":1136},[875,877,894,897,900,907,911,914,917,921,924,927,934,938,941,944,948,951,954,957,960,963,966,973,977,980,983,986,993,997,999,1002,1005,1008,1011,1014,1021,1025,1027,1030,1033,1036,1039,1042,1045,1048,1051,1053,1056,1059,1062,1064],[12,876,15],{"id":14},[17,878,879,882,885,888,891],{},[20,880,881],{},"Organ shortages leave thousands of patients waiting for lifesaving transplants each year.",[20,883,884],{},"Scientists are developing lab-grown tissues and organs through regenerative medicine and bioengineering.",[20,886,887],{},"One major challenge is creating blood vessel networks that can keep engineered tissues alive.",[20,889,890],{},"Recent breakthroughs in vascularized tissues are bringing researchers closer to transplantable artificial organs.",[20,892,893],{},"These advances could transform transplantation, personalized medicine, and future healthcare.",[36,895,896],{},"A patient waiting for a heart, kidney, or liver transplant may spend months or even years hoping a donor organ becomes available. For many patients, that organ never comes. Scientists are now working toward a different solution: growing replacement tissues and organs in the laboratory through regenerative medicine and bioengineering.",[36,898,899],{},"Organ transplantation has saved millions of lives, but the global demand for donor organs continues to exceed the available supply. According to Martin et al. (2025), thousands of patients worldwide remain dependent on transplant waiting lists because the amount of donated organs cannot meet the medical demand. This global shortage is reflected in the United States, where tens of thousands of patients continue to wait for lifesaving organ transplants each year, as shown in Figure 1.",[36,901,902],{},[60,903],{"alt":904,"className":905,"src":906,"style":66},"Transplant waiting lists",[64],"\u002Fnewsletter\u002Flaborgans\u002Ffig1.png",[36,908,910],{"className":909},[70,71],"Figure 1. Kidney and liver transplant waiting lists in the United States (2013–2024). The number of patients awaiting kidney and liver transplantation remained consistently high over the past decade, reflecting the persistent demand for donor organs.\nAdapted from OPTN\u002FSRTR (2024).\n",[36,912,913],{},"Because donor organs remain in critically short supply, scientists are developing new ways to create replacement tissues in the laboratory. One promising solution is regenerative medicine, which has allowed researchers to create increasingly sophisticated laboratory-grown tissues. Where scientists were once limited to growing simple layers of cells, they can now develop organoids, tissue-engineered structures, tissue patches, organ-on-chip systems, and 3D bioprinted tissues that mimic certain features of human organs. Advances in tissue engineering and 3D bioprinting have allowed scientists to precisely arrange cells and biomaterials into organized patterns, making engineered tissues more biologically realistic. These technologies have improved disease modeling, drug testing, tissue repair research, and the development of potential future therapies. However, fully functional transplantable organs have not yet been achieved. One of the greatest challenges is vascularization—the development of blood vessel networks capable of delivering oxygen and nutrients throughout large engineered tissues to keep them alive.",[36,915,916],{},"One of the most active areas of research focuses on vascularization, or building blood vessel networks within engineered tissues. Recent advances in this area have significantly improved scientists' ability to keep larger lab-grown tissues alive.",[12,918,920],{"id":919},"how-scientists-build-living-tissues","How Scientists Build Living Tissues",[36,922,923],{},"The foundation of many regenerative medicine technologies is the use of stem cells. Stem cells are unique because they can develop into specialized cell types found throughout the human body. Depending on the signals they receive, stem cells can become heart cells, liver cells, kidney cells, nerve cells, and many other types of tissue. This flexibility makes them an important tool for researchers attempting to create replacement tissues and study how organs develop.",[36,925,926],{},"To build living tissues, scientists use a process known as tissue engineering, as illustrated in Figure 2. Tissue engineering combines biology, engineering, and materials science to create structures that imitate natural tissues. Researchers often begin with stem cells because they can develop into the specialized cells needed for different tissues. These cells are combined with biomaterials that provide structural support and engineered scaffolds that organize them into specific shapes. The cells then multiply and mature, gradually forming living tissue within the scaffold. Once the engineered tissue becomes larger and more complex, however, cells located farther from the surface can no longer receive enough oxygen and nutrients through diffusion alone.",[36,928,929],{},[60,930],{"alt":931,"className":932,"src":933,"style":66},"Tissue engineering workflow",[64],"\u002Fnewsletter\u002Flaborgans\u002Ffig2.png",[36,935,937],{"className":936},[70,71],"Figure 2. Tissue engineering workflow illustrating the progression from stem cells to engineered tissue. As engineered tissues increase in size, oxygen diffusion becomes limited, creating the need for vascularization.\nCreated with BioRender.com.\n",[36,939,940],{},"This limitation creates one of the greatest obstacles to developing larger artificial tissues and organs: vascularization, the formation of blood vessels that deliver oxygen and nutrients throughout the tissue. All living tissues require a constant supply of oxygen and nutrients to survive. In the human body, blood vessels perform this function by transporting oxygen and nutrients to cells while removing waste products. Without a functional blood vessel network, cells located deep within engineered tissues cannot receive the resources they need to survive.",[36,942,943],{},"As engineered tissues increase in size, this problem becomes even more significant. Small tissue structures may survive through simple diffusion of oxygen and nutrients, but larger tissues require their own circulation systems. Creating stable blood vessel networks capable of supporting complex tissues remains one of the greatest challenges in regenerative medicine and a critical step toward developing fully transplantable artificial organs.",[12,945,947],{"id":946},"breakthrough-story-solving-the-vascularization-challenge","Breakthrough Story: Solving the Vascularization Challenge",[36,949,950],{},"For years, scientists could grow human cells and create small pieces of tissue in the laboratory. The real challenge began when they tried to make those tissues larger. Cells deep inside engineered tissues often died because oxygen and nutrients could not reach them.",[36,952,953],{},"Researchers soon realized that building an artificial organ would require much more than growing the right cells. Every organ in the human body depends on an extensive network of blood vessels that continuously delivers oxygen and removes waste. Without a similar system, lab-grown tissues could never survive long enough to function as replacement organs.",[36,955,956],{},"Early tissue-engineering efforts focused on creating simple tissue structures and developing scaffolds that could support growing cells. These approaches helped researchers organize cells into more realistic arrangements, but they still could not reproduce the circulation systems found in natural organs.",[36,958,959],{},"To address this problem, scientists began designing artificial vascular channels—small pathways that mimic blood vessels. Advances in biomaterials allowed these channels to be incorporated into engineered tissues, improving the movement of nutrients and oxygen throughout the structure.",[36,961,962],{},"A major turning point came with the development of 3D bioprinting. Instead of allowing cells to grow randomly, researchers could precisely place cells and biomaterials into specific patterns. Scientists began printing tissues with embedded vascular channels, bringing engineered tissues one step closer to functioning like natural organs.",[36,964,965],{},"One example is the Sacrificial Writing Into Functional Tissue (SWIFT) biomanufacturing process, shown in Figure 3, which uses a temporary \"sacrificial\" ink to create hollow vascular channels within densely packed stem cell–derived tissues. After the ink is removed, these channels can be perfused with oxygen and nutrients, helping engineered tissues survive and function more like natural organs.",[36,967,968],{},[60,969],{"alt":970,"className":971,"src":972,"style":66},"SWIFT biomanufacturing",[64],"\u002Fnewsletter\u002Flaborgans\u002Ffig3.png",[36,974,976],{"className":975},[70,71],"\nFigure 3. SWIFT biomanufacturing process for vascularized engineered tissue. Stem cell–derived organoids are compacted into a living tissue matrix, where sacrificial bioprinting creates hollow vascular channels for tissue perfusion. This approach helps overcome one of the major challenges in engineering transplantable tissues.\nAdapted from Skylar-Scott et al. (2019).\n",[36,978,979],{},"Recent advances have accelerated progress even further. Researchers have developed vascularized organoids-on-chip (Figure 4) that combine miniature organ models with functional circulation systems, allowing tissues to behave more like those found in the human body. These systems use several vascularization strategies, including endothelial cell coculture, gene overexpression, organoid fusion, and microfluidic perfusion to support blood vessel formation. Other teams have also reported implantable vascularized tissue constructs designed to promote blood vessel growth after transplantation. These advances provide researchers with new ways to study how engineered tissues survive, grow, and interact with living environments.",[36,981,982],{},"One of the most ambitious projects currently underway is a Stanford-led effort to bioprint a human heart and eventually implant it into a pig. Researchers are combining stem-cell biology, tissue engineering, and advanced bioprinting technologies to create heart tissue with the vascular networks needed to keep it alive. Although fully transplantable artificial hearts remain a long-term goal, projects like this demonstrate how rapidly the field is advancing.",[36,984,985],{},"Taken together, these advances illustrate a clear progression in regenerative medicine. Researchers first addressed the challenge of keeping engineered tissues alive by developing artificial vascular channels and later refined these approaches through 3D bioprinting and vascularized organoids-on-chip. Today, ambitious projects such as Stanford's effort to bioprint a human heart demonstrate how these innovations are bringing scientists closer to creating transplantable artificial organs.",[36,987,988],{},[60,989],{"alt":990,"className":991,"src":992,"style":66},"Varying vascularization strategies",[64],"\u002Fnewsletter\u002Flaborgans\u002Ffig4.png",[36,994,996],{"className":995},[70,71],"\nFigure 4. Strategies for vascularizing engineered organoids. Endothelial cell coculture, gene overexpression, organoid fusion, and microfluidic organoid-on-chip technology promote blood vessel formation and improve oxygen and nutrient delivery within engineered tissues.\nAdapted from Tan et al. (2023).\n",[12,998,719],{"id":718},[36,1000,1001],{},"Although advances in vascularized tissue engineering have brought scientists closer to creating artificial organs, several major challenges must still be overcome before these technologies can become routine medical treatments. Successfully growing living tissue in the laboratory is only the first step; researchers must also ensure that engineered organs can be produced at a practical scale, remain affordable, function safely in patients, and meet strict regulatory standards.",[36,1003,1004],{},"One of the greatest challenges is scalability. Creating small engineered tissues is much easier than producing full-sized organs with the same level of complexity found in the human body. Natural organs contain billions of cells organized into highly structured systems, and reproducing this organization on a large scale remains a major difficulty.",[36,1006,1007],{},"Even if scientists can overcome this challenge, cost remains another significant barrier. Many regenerative medicine technologies require advanced equipment, specialized materials, and highly trained researchers. The resources needed to create and test engineered tissues can be expensive, meaning that reducing costs will be necessary before these treatments can become accessible to more patients.",[36,1009,1010],{},"Beyond manufacturing and cost, researchers must also demonstrate that engineered organs are safe for long-term use. Before these tissues can be implanted into patients, scientists must prove that they can function properly over extended periods and interact safely with the human body. Continued research is needed to understand how engineered tissues perform after transplantation and how the body responds to them.",[36,1012,1013],{},"Finally, even after these scientific and medical challenges are addressed, engineered organs must undergo extensive regulatory review before they can be used in clinical practice. Because these technologies combine biology, engineering, and medicine, they must be thoroughly evaluated to demonstrate their safety and effectiveness before receiving approval for clinical applications.",[36,1015,1016],{},[60,1017],{"alt":1018,"className":1019,"src":1020,"style":66},"Several approaches to biomanufacturing over the years",[64],"\u002Fnewsletter\u002Flaborgans\u002Ffig5.png",[36,1022,1024],{"className":1023},[70,71],"\nFigure 5. Evolution of tissue engineering technologies from early cell-based approaches to modern regenerative medicine strategies, including organoids, 3D bioprinting, organ-on-a-chip systems, and whole-organ engineering.\nAdapted from Hoang et al. (2025).\n",[12,1026,735],{"id":734},[36,1028,1029],{},"The development of lab-grown tissues and artificial organs has the potential to transform modern medicine. One of the most significant benefits could be a reduced dependence on donor organs. If scientists can successfully create transplantable organs in the laboratory, patients may no longer need to spend years on transplant waiting lists or rely solely on donor availability. This could improve access to lifesaving treatments and help address the persistent shortage of donor organs.",[36,1031,1032],{},"These technologies may also advance personalized medicine. Researchers are exploring ways to create engineered tissues using a patient's own cells, which could reduce the risk of immune rejection after transplantation. Personalized tissues may allow treatments to be tailored to individual patients, improving both safety and effectiveness.",[36,1034,1035],{},"Beyond transplantation, engineered tissues already play an important role in biomedical research. Organoids and other laboratory-grown tissue models allow scientists to study diseases and test potential treatments using systems that more closely resemble human biology. As these technologies continue to improve, they may help researchers develop safer and more effective therapies while reducing reliance on traditional testing methods.",[36,1037,1038],{},"The impact of regenerative medicine extends beyond transplant surgery. As scientists improve their ability to engineer functional tissues, future treatments may be able to repair or replace damaged organs instead of relying solely on donor transplantation. These advances could provide new treatment options for patients with severe injuries, congenital defects, and diseases that currently have few long-term solutions, fundamentally changing how many conditions are treated and improving long-term patient outcomes.",[36,1040,1041],{},"Researchers continue to refine the technologies discussed throughout this article. One major area of focus is improving vascularization so engineered tissues can develop stable blood vessel networks capable of supplying oxygen and nutrients after transplantation. Scientists are also advancing 3D bioprinting techniques to create increasingly complex tissues with more accurate biological structures. Continued progress in these areas will be essential for producing fully transplantable artificial organs that function like their natural counterparts.",[36,1043,1044],{},"The field of regenerative medicine also creates opportunities for a wide range of careers. Professionals in biomedical engineering, biotechnology, tissue engineering, clinical research, and regenerative medicine all contribute to the development of new therapies and technologies. Biomedical engineers design scaffolds and bioprinting systems, tissue engineers develop laboratory-grown tissues, clinical researchers evaluate the safety and effectiveness of new treatments, and biotechnology professionals help translate laboratory discoveries into therapies that can be manufactured and used in healthcare. Collaboration among these fields is essential for bringing engineered organs from the laboratory to patients.",[36,1046,1047],{},"If you've ever been interested in biology, engineering, medicine, or even computer design, regenerative medicine brings all of these fields together. Teams developing artificial organs often include biomedical engineers who design scaffolds and bioprinting systems, surgeons who determine how engineered organs can be safely transplanted into patients, stem-cell researchers who develop the living cells used to create tissues, software specialists who create imaging and bioprinting programs that guide tissue construction, and materials scientists who develop biomaterials that support cell growth and tissue formation. Together, these specialists combine their expertise to move regenerative medicine from laboratory research toward real-world medical treatments. The next generation of breakthroughs may come from students who choose to pursue careers in these fields.",[36,1049,1050],{},"Ultimately, the long-term implications of this research extend beyond individual technologies. As scientists improve their ability to create functional tissues and organs, medicine may gradually shift from relying primarily on organ donation toward manufacturing personalized replacement tissues. Although significant challenges remain, current advances suggest that this possibility is becoming increasingly realistic.",[12,1052,303],{"id":302},[36,1054,1055],{},"A decade ago, scientists could grow only small, simple tissues in the laboratory, and creating fully functional organs seemed like science fiction. As researchers developed artificial vascular networks, advanced 3D bioprinting techniques, and increasingly sophisticated organ-on-chip systems, each breakthrough brought them one step closer to overcoming the challenges that once limited the field. Today, the goal of creating transplantable artificial organs no longer feels impossible—it represents a rapidly advancing area of scientific research.",[36,1057,1058],{},"Significant challenges remain, including scalability, cost, safety, and regulatory approval. However, the progress made in vascularized tissue engineering demonstrates how quickly regenerative medicine is advancing. What once seemed impossible is gradually becoming a realistic scientific goal.",[36,1060,1061],{},"For students interested in medicine, biotechnology, engineering, or research, this field offers a glimpse into how scientific innovation can directly improve human lives. As scientists continue developing ways to create functional replacement tissues and organs, the future of healthcare may look very different from the one we know today.",[12,1063,322],{"id":321},[324,1065,1066,1073,1080,1087,1094,1101,1108,1115,1122,1129],{},[20,1067,1068,1069],{},"Alkazemi, H., Mitchell, G. M., Lokmic-Tomkins, Z., Heath, D. E., & O'Connor, A. J. (2024). Hierarchically vascularized and implantable tissue constructs created through angiogenesis from tissue-engineered vascular grafts. bioRxiv. ",[330,1070,1071],{"href":1071,"rel":1072},"https:\u002F\u002Fwww.biorxiv.org\u002Fcontent\u002F10.1101\u002F2024.04.29.591796v1",[334],[20,1074,1075,1076],{},"Hoang, V. T., Nguyen, Q. T., Phan, T. T. K., Pham, T. H., Dinh, N. T. H., Anh, L. P. H., Dao, L. T. M., Bui, V. D., Dao, H.-N., Le, D. S., Ngo, A. T. L., Le, Q.-D., & Nguyen Thanh, L. (2025). Tissue engineering and regenerative medicine: Perspectives and challenges. MedComm, 6(5), e70192. ",[330,1077,1078],{"href":1078,"rel":1079},"https:\u002F\u002Fdoi.org\u002F10.1002\u002Fmco2.70192",[334],[20,1081,1082,1083],{},"Lewis Lab. (n.d.). Three-dimensional bioprinting of thick vascularized tissues. Harvard John A. Paulson School of Engineering and Applied Sciences. ",[330,1084,1085],{"href":1085,"rel":1086},"https:\u002F\u002Flewisgroup.seas.harvard.edu\u002Fpublications\u002Fthree-dimensional-bioprinting-thick-vascularized-tissues",[334],[20,1088,1089,1090],{},"Martin, F., Carmona, M., Mahillo, B., Alvarez, M., Luengo, A., Chatzixiros, E., López-Fraga, M., Domínguez-Gil, B., & Tullius, S. G. (2025). Global organ donation and transplantation activities, 2024. Transplant International. ",[330,1091,1092],{"href":1092,"rel":1093},"https:\u002F\u002Fpmc.ncbi.nlm.nih.gov\u002Farticles\u002FPMC12908642\u002F",[334],[20,1095,1096,1097],{},"OPTN\u002FSRTR. (2024). 2024 annual data report: Overview of U.S. solid organ transplantation. ",[330,1098,1099],{"href":1099,"rel":1100},"https:\u002F\u002Fsrtr.hrsa.gov\u002Fadr\u002F2024\u002FOverview\u002F",[334],[20,1102,1103,1104],{},"Skylar-Scott, M. A., et al. (2023, September 12). Moonshot effort aims to bioprint a human heart and implant it in a pig. Stanford Report. ",[330,1105,1106],{"href":1106,"rel":1107},"https:\u002F\u002Fnews.stanford.edu\u002Fstories\u002F2023\u002F09\u002Fmoonshot-effort-aims-bioprint-human-heart-implant-pig",[334],[20,1109,1110,1111],{},"Skylar-Scott, M. A., Uzel, S. G. M., Nam, L. L., Ahrens, J. H., Truby, R. L., Damaraju, S., & Lewis, J. A. (2019). Biomanufacturing of organ-specific tissues with high cellular density and embedded vascular channels. Science Advances, 5(9), eaaw2459. ",[330,1112,1113],{"href":1113,"rel":1114},"https:\u002F\u002Fwww.science.org\u002Fdoi\u002F10.1126\u002Fsciadv.aaw2459",[334],[20,1116,1117,1118],{},"Tan, S. Y., Feng, X., Cheng, L. K. W., & Wu, A. R. (2023). Vascularized human brain organoid on-chip. Lab on a Chip, 23(12), 2693–2709. ",[330,1119,1120],{"href":1120,"rel":1121},"https:\u002F\u002Fdoi.org\u002F10.1039\u002Fd2lc01109c",[334],[20,1123,1124,1125],{},"U.S. Department of Health & Human Services. (n.d.). Organ donation statistics. OrganDonor.gov. ",[330,1126,1127],{"href":1127,"rel":1128},"https:\u002F\u002Fwww.organdonor.gov\u002Flearn\u002Forgan-donation-statistics\u002Fdetailed-description",[334],[20,1130,1131,1132],{},"Zhao, Y., Landau, S., Okhovatian, S., et al. (2024). Integrating organoids and organ-on-a-chip devices. Nature Reviews Bioengineering, 2, 588–608. ",[330,1133,1134],{"href":1134,"rel":1135},"https:\u002F\u002Fdoi.org\u002F10.1038\u002Fs44222-024-00207-z",[334],{"title":364,"searchDepth":365,"depth":365,"links":1137},[1138,1139,1140,1141,1142,1143,1144],{"id":14,"depth":365,"text":15},{"id":919,"depth":365,"text":920},{"id":946,"depth":365,"text":947},{"id":718,"depth":365,"text":719},{"id":734,"depth":365,"text":735},{"id":302,"depth":365,"text":303},{"id":321,"depth":365,"text":322},"2026-07-15","Researchers are advancing bioengineered, vascularized tissues to overcome blood supply challenges and permanently change organ transplantation.",{"image":1020},"\u002Fnewsletter\u002Flaborgans",{"title":872,"description":1146},"newsletter\u002Flaborgans","8s7Kg6pgdlmaF6X2lznxzxC5qzXiVToAIPA9SkvsGxg",{"id":1153,"title":1154,"author":1155,"body":1156,"date":1327,"description":1328,"extension":378,"meta":1329,"navigation":380,"path":1330,"seo":1331,"stem":1332,"__hash__":1333},"newsletter\u002Fnewsletter\u002Ftoxicmasc.md","Toxic Masculinity: the Scientific and Societal Perspectives of the Mask","Kaitlin Lee",{"type":9,"value":1157,"toc":1319},[1158,1160,1177,1181,1184,1187,1195,1198,1201,1212,1215,1219,1222,1229,1233,1236,1239,1242,1246,1253,1257,1260,1278,1281,1284,1288,1291,1294,1296,1299,1306,1313,1316],[12,1159,15],{"id":14},[17,1161,1162,1165,1168,1171,1174],{},[20,1163,1164],{},"Traditional toxic masculinity is based on 3 factors: emotional suppression, aggression, and self reliance.",[20,1166,1167],{},"Emotional suppression changes brain physiology",[20,1169,1170],{},"Anger and dominance creates issues with socializing",[20,1172,1173],{},"The impact may create difficulties in SSRI treatment",[20,1175,1176],{},"Instead, somatic therapy may reverse some of the brain physiology changes.",[12,1178,1180],{"id":1179},"intro","Intro",[36,1182,1183],{},"Social media is a tool for people to express themselves. But if you go on any social media platform, you can see a guy posting unbothered fitness pictures, with corny slogans and stoic expressions. Yet, behind the scenes, they may be suffering from anxiety and loneliness. Society pushes the idea that individuals should hide behind a mask of being unemotional, and this can lead to neurological changes in the brain.",[36,1185,1186],{},"The general definition is,",[1188,1189,1190],"blockquote",{},[36,1191,1192],{},[90,1193,1194],{},"the cultural pressure on men and boys to conform to rigid, restrictive gender norms",[36,1196,1197],{},"But what does this actually mean? Is there data to prove this?",[36,1199,1200],{},"Toxic masculinity usually needs 3 factors:",[17,1202,1203,1206,1209],{},[20,1204,1205],{},"Emotional suppression",[20,1207,1208],{},"Aggression and dominance",[20,1210,1211],{},"Extreme self reliance",[36,1213,1214],{},"Toxic masculinity is a system of social expectations that separates what it means to be a “man” and a “woman”.",[12,1216,1218],{"id":1217},"traditional-toxic-masculinity","Traditional Toxic Masculinity",[36,1220,1221],{},"Men are usually told to suppress their emotions since childhood because it does not fit the stereotypical picture of what a man is supposed to do. The emotional suppression can alter the brain by affecting the amygdala, the part of the brain that controls emotional and threat regulation. If a person continuously perceives everyone as a threat and suppresses other emotions, it raises cortisol levels. This can consistently raise cortisol levels over time, even in situations that do not need extreme measures. This can lead to emotional outbursts and can unnecessarily trigger “fight or flight” responses in safe situations.",[36,1223,1224],{},[60,1225],{"alt":1226,"className":1227,"src":1228,"style":66},"FMRI image of repressed negative emotions",[64],"\u002Fnewsletter\u002Ftoxicmasc\u002Fbs1.png",[36,1230,1232],{"className":1231},[70,71],"Schematic representation of amygdala-prefrontal connectivity. Adapted from “Anxiety shapes amygdala-prefrontal dynamics during movie watching”, by Kirk, P. A., Holmes, A. J., & Robinson, O. J., 2023, Biological Psychiatry Global Open Science.",[36,1234,1235],{},"People are more than twice as likely to be diagnosed with clinical depression and three times more likely to encounter memory loss in high stress events due to the hippocampus also shrinking. By continuously triggering stress responses, it creates a cycle of enlarging the amygdala and increasing anxiety, which could potentially cause more stress, which can create patterns of unhealthy behavior that show up in all areas of life.",[36,1237,1238],{},"Additionally, because individuals are told to be “unemotional”, they miss out on opportunities of oxytocin, otherwise known as the “love hormone”, a vital component of social connection. The lack of social connection can drive a person further down a path of depression and anxiety.",[36,1240,1241],{},"As a result, anger and dominance may be demonstrated as the only “acceptable” output for stress. Because of this, many men use it as a tool to maintain emotional distance with others and create favorable power dynamics. These power dynamics are usually created based on physical traits, such as who is more fit, or who has the least amount of perceived “feminine” qualities. In group settings, need for dominance can create insecurities and conflicts between people in a way that perpetuates the need for feelings of power. Traditional toxic masculinity has many different signals with emotional suppression, anger and dominance, and how these traits can affect a person–mentally and scientifically.",[12,1243,1245],{"id":1244},"impact","Impact",[36,1247,1248],{},[60,1249],{"alt":1250,"className":1251,"src":1252,"style":66},"SPECT image of cortisol impact",[64],"\u002Fnewsletter\u002Ftoxicmasc\u002Fbs2.png",[36,1254,1256],{"className":1255},[70,71],"Comparison of normal vs. depressed baseline brain metabolism via SPECT imaging. From “Brain SPECT Scans in Depression”, by Amen Clinics, 2019, Dr. Sarah Edwards Portal.",[36,1258,1259],{},"Traditional toxic masculinity can lead to impacts in the brain and how society can change their daily life. The brain scan above displays the increased amount of cortisol (red) that comprise overly anxious brains. The scan on the right shows a healthy brain while the one on the left has been exposed to too much cortisol, flooding other components of the brain. Emotional suppression often leaves individuals in double jeopardy–since vulnerability is viewed as a weakness, people typically do not seek medicinal help or community support. This makes receiving clinical treatment and therapy more difficult because the emotional suppression functions as a barrier, making it harder for standard, talk-heavy therapy sessions. As a result, annually,",[17,1261,1262,1275],{},[20,1263,1264,1265],{},"1 in 5 men are diagnosed with a mental health condition, but only about 41.6% of men receive treatment\n",[17,1266,1267],{},[20,1268,1269,1270],{},"For reference, 57% of women seek help for a mental health condition.\n",[17,1271,1272],{},[20,1273,1274],{},"Men could feel this way due to fear of not conforming to “normal” behavior.",[20,1276,1277],{},"Men have accounted for roughly 78% of all suicides.",[36,1279,1280],{},"As stated earlier, people will typically not seek medicinal help because of society’s effect on them. Instead, people may attempt to “fix” the problem themself. By rewiring the brain's thinking, the brain can no longer respond to standard depression treatments. Depression is normally treated with SSRIs (selective serotonin reuptake inhibitors). However, SSRIs depend on the neuroplasticity of a healthy hippocampus to stimulate new neurons to improve mood. Since emotional suppression shrinks the hippocampus, if a clinician prescribes SSRI to a person whose hippocampus has been structurally damaged over time, the medication is significantly less likely to work, as the neurological architecture that the treatment requires has been degraded.",[36,1282,1283],{},"Consequently, the physiological changes in the brain that result from emotional suppression because traditional therapies typically used for depressed patients are not as effective. Instead, modern solutions must accommodate the biology and adjustments in the brain over long periods of emotional suppression in toxic masculinity.",[12,1285,1287],{"id":1286},"solution","Solution",[36,1289,1290],{},"Although having to confront toxic masculinity is still a common experience, destigmatizing language is slowly becoming more widespread, encouraging more people to process their emotions and become more vulnerable and open to treatment. Additionally, the neurological effects of toxic masculinity can be reversed since the brain can adapt in response to positive emotional changes.",[36,1292,1293],{},"Currently, somatic and mind-body integration is being tested as a treatment for these types of mental health issues. Since chronic emotional suppression locks emotion in the body, modern treatment uses heavy physical routines to try and use continuous loops in the routine to try and deregulate a hyper-aware amygdala. The physical routines can include tracking sleep cycles, regulated strength training, and monitoring cardiovascular health. More research is being released to learn more about the effects of toxic masculinity and how society as a whole can fight against it.",[12,1295,322],{"id":321},[36,1297,1298],{},"American Psychological Association. (2018). APA guidelines for psychological practice with boys and men. American Psychological Association.",[36,1300,1301,1302],{},"Goldin, P. R., McRae, K., Ramel, W., & Gross, J. J. (2008). The neural bases of emotion regulation: Reappraisal and suppression of negative emotion. Biological Psychiatry, 63(6), 577-586. ",[330,1303,1304],{"href":1304,"rel":1305},"https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.biopsych.2007.05.031",[334],[36,1307,1308,1309],{},"Hogeveen, J., & Grafman, J. (2021). Alexithymia. Handbook of Clinical Neurology, 47-62. ",[330,1310,1311],{"href":1311,"rel":1312},"https:\u002F\u002Fdoi.org\u002F10.1016\u002Fb978-0-12-822290-4.00004-9",[334],[36,1314,1315],{},"Munsch, C. (2016). Relative income, psychological well-being, and health: Is breadwinning hazardous or protective? American Sociological Review, 81(4), 705-727.",[36,1317,1318],{},"The impact of traditional masculinity norms on men's willingness to seek mental health support: A systematic review of literature. (2025). American Journal of Men's Health, 19(3), 1-15. PubMed Central. pmc.ncbi.nlm.nih.gov\u002Farticles\u002FPMC12117241\u002F",{"title":364,"searchDepth":365,"depth":365,"links":1320},[1321,1322,1323,1324,1325,1326],{"id":14,"depth":365,"text":15},{"id":1179,"depth":365,"text":1180},{"id":1217,"depth":365,"text":1218},{"id":1244,"depth":365,"text":1245},{"id":1286,"depth":365,"text":1287},{"id":321,"depth":365,"text":322},"2026-07-12","Toxic masculinity is a system of social expectations that separates what it means to be a “man” and a “woman”, but why do these beliefs grow, what are their impacts, and how can they be resolved?",{"image":1228},"\u002Fnewsletter\u002Ftoxicmasc",{"title":1154,"description":1328},"newsletter\u002Ftoxicmasc","jFnVIYIdO-cEa-lcbQHDl77GoWDRSwWuEP1qnDSwVTY",{"id":1335,"title":1336,"author":388,"body":1337,"date":1581,"description":1582,"extension":378,"meta":1583,"navigation":380,"path":1584,"seo":1585,"stem":1586,"__hash__":1587},"newsletter\u002Fnewsletter\u002Fcftr.md","The “New Kid” of Medicine: CFTR Modulator Therapies",{"type":9,"value":1338,"toc":1571},[1339,1341,1355,1357,1360,1363,1378,1382,1385,1388,1411,1415,1418,1425,1430,1433,1436,1440,1443,1446,1449,1451,1454,1457,1459,1462,1465,1478,1493,1505,1519,1530,1544,1558],[12,1340,15],{"id":14},[17,1342,1343,1346,1349,1352],{},[20,1344,1345],{},"Cystic Fibrosis (CF) is an inherited genetic disorder causing thick, sticky mucus to accumulate in the lungs and digestive system",[20,1347,1348],{},"CF is caused by a mutation in the CFTR gene, which affects salt and water balance in cells",[20,1350,1351],{},"CFTR modulator therapies are oral drugs that fix the malfunctioning CFTR protein",[20,1353,1354],{},"Correctors help the protein fold correctly and potentiators help the protein channel open",[12,1356,413],{"id":412},[36,1358,1359],{},"Buddhist monk and peace activist Thich Nhat Hanh said \"breath is the bridge which connects life to consciousness, which unites your body to your thoughts.\" The act of breathing restores the connection between physical sensations and mental states. This is something most of us never think twice about. But for roughly 1 in 25 Americans, every breath is a conscious, labored effort. These are people living with Cystic Fibrosis (CF), a disease that turns one of the body's most automatic functions into a daily struggle.",[36,1361,1362],{},"Cystic Fibrosis is an inherited genetic disorder causing thick, sticky mucus to accumulate in the lungs and digestive system, resulting in severe organ damage and frequent infections.  It is one of the most common genetic diseases among Caucasian populations–though it affects individuals of all racial and ethnic backgrounds–with approximately 40,000 children and adults in the United States and an estimated 100,000 to 160,000 people globally (Scotet). However, despite the significant number of infected individuals, an effective cure has yet to be developed. Significant research gaps exist, primarily driven by genetic exclusivity, varying clinical responses, long-term safety profiles, and prohibitive global healthcare costs. This is where modulator therapies come in.",[1364,1365,1367,1368,1367,1373],"div",{"style":1366},"display: flex; justify-content: center; align-items: center; gap: 20px;","\n  ",[60,1369],{"src":1370,"alt":1371,"className":1372},"\u002Fnewsletter\u002Fcftr\u002Fcf.png","Cystic Fibrosis Depiction",[64],[60,1374],{"src":1375,"alt":1376,"className":1377},"\u002Fnewsletter\u002Fcftr\u002Fcases.png","Cystic Fibrosis Cases",[64],[12,1379,1381],{"id":1380},"cftr-modulator-therapies","CFTR Modulator Therapies",[36,1383,1384],{},"CFTR modulator therapies are transformative oral drugs that treat the underlying cause of CF by fixing the malfunctioning CFTR protein, rather than just managing the symptoms. These therapies improve lung function, weight (BMI), and quality of life for people with specific CF mutations. For over 90% of CF patients with specific genetic mutations, these drugs significantly slow disease progression and extend lifespans (Chun). The most surprising part? They’re fresh off the boat. First introduced in 2012, it was a major breakthrough. It holds the title as the first drug to target the foundational factor of Cystic Fibrosis rather than just its symptoms. In 2019, key modulator Elexacaftor\u002Ftezacaftor\u002Fivacaftor (Trikafta) was approved. It is a modulator different from the ones that preceded it, treating approximately 90% of cystic fibrosis patients, including those with just one copy of the F508del mutation (Rubin).",[36,1386,1387],{},"Cystic Fibrosis is caused by a mutation in the CFTR gene, which affects salt and water balance in cells (by producing a dysfunctional protein that fails to transport chloride and water across cell membranes). Thus, modulator therapies work by allowing chloride to move into cells, keeping mucus thin and preventing buildup in organs. There are two main types: correctors (help the protein fold correctly and reach the cell surface) and potentiators (help the protein channel open).",[1364,1389,1367,1393,1367,1398],{"className":1390},[1391,1392],"flex","gap-20",[60,1394],{"src":1395,"alt":1396,"className":1397},"\u002Fnewsletter\u002Fcftr\u002Fapproval.png","CFTR Approval",[64],[1364,1399,1404,1405,1404,1408],{"className":1400},[1391,1401,1402,1403],"flex-col","items-center","justify-center","\n    ",[36,1406,1407],{},"Restoration of CFTR function has been associated with improved airway surface hydration and addition to increased airway surface fluid pH",[36,1409,1410],{},"CFTR Modulator Therapies: Potential Impact on Airway Infections in Cystic Fibrosis”, Saluzzo, 2022, NCBI",[12,1412,1414],{"id":1413},"potentiators","Potentiators",[36,1416,1417],{},"The CFTR protein functions like a channel or tunnel with a gate that controls the movement of chloride ions. Potentiators are a type of CFTR modulator that keep this gate open, allowing chloride to pass more easily through the cell membrane.",[36,1419,1420],{},[60,1421],{"alt":1422,"className":1423,"src":1424,"style":66},"Potentiators in the cell",[64],"\u002Fnewsletter\u002Fcftr\u002Fprotein.png",[36,1426,1429],{"className":1427},[70,1428,71],"text-neutral-700","(Han)",[36,1431,1432],{},"Ivacaftor (Kalydeco) is an example of a potentiator. It is beneficial for people with gating and conduction mutations, as well as certain residual function and splice mutations that result in reduced amounts of normal CFTR protein (MedChemExpress). In these types of mutations, some CFTR protein is able to reach the cell surface, but either the quantity is too low or the protein does not transport enough chloride across the membrane.",[36,1434,1435],{},"By increasing the amount of time the CFTR channel remains open, potentiators enhance chloride movement through the cell membrane. This improved chloride transport helps restore CFTR function and can reduce the symptoms associated with cystic fibrosis.",[12,1437,1439],{"id":1438},"correctors","Correctors",[36,1441,1442],{},"Corrector medications help the CFTR protein fold into its proper three-dimensional structure, allowing it to travel, or “traffic,” to the cell surface where it can function.",[36,1444,1445],{},"Approximately 85% of individuals with Cystic Fibrosis carry at least one copy of the F508del mutation (Editorial). This mutation causes the CFTR protein to misfold, preventing it from developing the correct shape. Corrector therapies improve the protein’s folding, help it reach the cell surface, and increase the amount of time it remains there. However, these drugs cannot fully correct the folding defect, so only a portion of the CFTR proteins successfully reach the cell membrane. In addition, the proteins that do arrive at the surface do not open effectively enough to allow adequate chloride transport out of the cell.",[36,1447,1448],{},"When a corrector is combined with a potentiator, such as ivacaftor, the potentiator helps keep the CFTR channel open. This allows more chloride to move through the channel, which can help lessen the symptoms of CF.",[12,1450,303],{"id":302},[36,1452,1453],{},"Ultimately, CFTR modulator therapies have revolutionized the treatment of Cystic Fibrosis by addressing the root cause of the disease rather than simply treating its indicators.",[36,1455,1456],{},"The research and information of these modulators would not have been possible without the courage of the patients who participated in clinical trials and chose to use these new therapies despite the uncertainties involved. As research continues and new modulators are developed, there is growing hope that people with Cystic Fibrosis will be able to live longer, healthier lives. The progress made through CFTR modulator therapies demonstrates how innovation and perseverance can work together to change the future of a disease that once had very limited treatment options.",[470,1458],{},[473,1460,477],{"className":1461,"id":476},[71],[470,1463],{"className":1464},[481,482,483],[36,1466,1467,1468,1471,1472,1477],{},"Chalmers, Sarah. “Cystic Fibrosis.” ",[90,1469,1470],{},"Mayo Clinic",", Mayo Clinic, 7 Dec. 2024, ",[330,1473,1476],{"href":1474,"rel":1475},"https:\u002F\u002Fwww.mayoclinic.org\u002Fdiseases-conditions\u002Fcystic-fibrosis\u002Fsymptoms-causes\u002Fsyc-2035370",[334],"www.mayoclinic.org\u002Fdiseases-conditions\u002Fcystic-fibrosis\u002Fsymptoms-causes\u002Fsyc-2035370",".",[36,1479,1480,1481,1484,1485,1488,1489,1477],{},"Chun, Stanford W., et al. “Highly Effective Cystic Fibrosis Transmembrane Conductance (Regulator) Modulator Therapy: Shifting the Curve for Most While Leaving Some Further Behind.” ",[90,1482,1483],{},"Current Opinion in Pediatrics",", vol. 36, no. 3, 2024, pp. 290–295. ",[90,1486,1487],{},"PubMed",", ",[330,1490,1491],{"href":1491,"rel":1492},"https:\u002F\u002Fdoi.org\u002F10.1097\u002FMOP.0000000000001384",[334],[36,1494,1495,1496,1499,1500,1477],{},"Editorial Team. “How Does Cystic Fibrosis Develop?” ",[90,1497,1498],{},"Cystic-Fibrosis.com",", 15 Aug. 2019, ",[330,1501,1504],{"href":1502,"rel":1503},"https:\u002F\u002Fcystic-fibrosis.com\u002Fpathophysiology",[334],"cystic-fibrosis.com\u002Fpathophysiology",[36,1506,1507,1508,1511,1512,1488,1515,1477],{},"Han, Xiao Xuan, et al. “Recommended Tool Compounds for Modifying the Cystic Fibrosis Transmembrane Conductance Regulator Channel Variants.” ",[90,1509,1510],{},"ACS Pharmacology & Translational Science",", vol. 7, no. 4, 14 Mar. 2024, pp. 1021–1035. ",[90,1513,1514],{},"ACS Publications",[330,1516,1517],{"href":1517,"rel":1518},"https:\u002F\u002Fdoi.org\u002F10.1021\u002Facsptsci.3c00362",[334],[36,1520,1521,1522,1488,1525,1529],{},"MedChemExpress. “CFTR Targets.” ",[90,1523,1524],{},"MedChemExpress",[330,1526,1527],{"href":1527,"rel":1528},"https:\u002F\u002Fwww.medchemexpress.com\u002FTargets\u002FCFTR.html",[334],". Accessed 16 Aug. 2026.",[36,1531,1532,1533,1536,1537,1488,1540,1477],{},"Rubin, Jaime L., et al. “Impact of CFTR Modulators on Longitudinal Cystic Fibrosis Survival and Mortality: Review and Secondary Analysis.” ",[90,1534,1535],{},"Pulmonary Therapy",", vol. 11, no. 3, 2025, pp. 365–386. ",[90,1538,1539],{},"SpringerLink",[330,1541,1542],{"href":1542,"rel":1543},"https:\u002F\u002Fdoi.org\u002F10.1007\u002Fs41030-025-00303-4",[334],[36,1545,1546,1547,1550,1551,1488,1554,1477],{},"Saluzzo, Francesca, et al. “CFTR Modulator Therapies: Potential Impact on Airway Infections in Cystic Fibrosis.” ",[90,1548,1549],{},"Cells",", vol. 11, no. 7, 6 Apr. 2022, art. 1243. ",[90,1552,1553],{},"MDPI",[330,1555,1556],{"href":1556,"rel":1557},"https:\u002F\u002Fdoi.org\u002F10.3390\u002Fcells11071243",[334],[36,1559,1560,1561,1564,1565,1488,1567,1477],{},"Scotet, Virginie, et al. “The Changing Epidemiology of Cystic Fibrosis: Incidence, Survival and Impact of the CFTR Gene Discovery.” ",[90,1562,1563],{},"Genes",", vol. 11, no. 6, 26 May 2020, art. 589. ",[90,1566,1553],{},[330,1568,1569],{"href":1569,"rel":1570},"https:\u002F\u002Fdoi.org\u002F10.3390\u002Fgenes11060589",[334],{"title":364,"searchDepth":365,"depth":365,"links":1572},[1573,1574,1575,1576,1577,1578],{"id":14,"depth":365,"text":15},{"id":412,"depth":365,"text":413},{"id":1380,"depth":365,"text":1381},{"id":1413,"depth":365,"text":1414},{"id":1438,"depth":365,"text":1439},{"id":302,"depth":365,"text":303,"children":1579},[1580],{"id":476,"depth":530,"text":477},"2026-06-29","CFTR Modulator therapies are some of the best tools we have against Cystic Fibrosis, that attack the disease at its heart.",{"image":1370},"\u002Fnewsletter\u002Fcftr",{"title":1336,"description":1582},"newsletter\u002Fcftr","5-BarSFD6jiSGM8uToGw0-0cyDKCDgKQwVVMzp2A3jE",{"id":1589,"title":1590,"author":7,"body":1591,"date":1852,"description":1853,"extension":378,"meta":1854,"navigation":380,"path":1855,"seo":1856,"stem":1857,"__hash__":1858},"newsletter\u002Fnewsletter\u002Fcasgevy.md","Casgevy: CRISPR Gene Therapy for Sickle Cell Disease",{"type":9,"value":1592,"toc":1842},[1593,1595,1612,1614,1617,1620,1623,1626,1633,1636,1639,1646,1650,1654,1657,1660,1663,1666,1673,1677,1680,1687,1691,1695,1698,1701,1704,1707,1711,1714,1717,1720,1723,1727,1730,1733,1736,1740,1743,1746,1749,1751,1754,1757,1760,1762],[12,1594,15],{"id":14},[17,1596,1597,1600,1603,1606,1609],{},[20,1598,1599],{},"Casgevy is the first FDA-approved CRISPR-based therapy for sickle cell disease, treating disease at the genetic level by editing hematopoietic stem cells rather than managing symptoms.",[20,1601,1602],{},"The therapy increases fetal hemoglobin production, which prevents red blood cells from sickling under low oxygen conditions.",[20,1604,1605],{},"Clinical trials show a significant reduction in vaso-occlusive crises and other severe complications.",[20,1607,1608],{},"This development represents a shift in medicine from symptom-based treatment to targeted genetic intervention at the cellular level.",[20,1610,1611],{},"Readers will learn how sickle cell disease develops, how CRISPR-Cas9 works, and how Casgevy is applied clinically as a treatment.",[470,1613],{},[36,1615,1616],{},"A teenager living with severe sickle cell disease can experience sudden, intense pain crises that interrupt school, sleep, and daily life without warning. For years, treatment has focused mainly on managing these symptoms rather than addressing the underlying cause. That approach is now beginning to change with the emergence of CRISPR-based gene editing therapies such as Casgevy, which target the disease at its genetic source.",[36,1618,1619],{},"Sickle cell disease originates from a single-nucleotide mutation in the β-globin gene. That small genetic change alters the structure of hemoglobin, the oxygen-carrying protein in red blood cells. Under low oxygen conditions, the altered hemoglobin tends to stick together, forming rigid fibers that distort normally flexible red blood cells into a sickle shape, as shown in Figure 2. These cells struggle to pass through blood vessels, restricting circulation and reducing oxygen delivery. The result is a cascade of clinical effects, including severe pain episodes, chronic anemia, stroke risk, and cumulative organ damage.",[36,1621,1622],{},"At the core of this process is a central principle in biology: genetic information flows from DNA to RNA to proteins. This pathway determines how instructions encoded in DNA ultimately become functional molecules inside cells. When a single nucleotide in DNA’s genetic code is mutated, the downstream effects can change protein structure in a way that reshapes how entire cells behave. In sickle cell disease, that molecular-level disruption scales into a systemic disorder affecting the circulatory system as a whole.",[36,1624,1625],{},"This connection between DNA and the translation of DNA to protein function is precisely what makes gene editing so powerful. CRISPR-Cas9 is a programmable gene-editing system that uses a guide RNA, a short RNA sequence that matches a target DNA sequence, to locate a specific DNA region, while the Cas9 enzyme makes a cut at that site. Once the DNA is cut, the cell activates its own DNA repair machinery. Rather than replacing entire genes, CRISPR leverages these repair processes to alter gene regulation in highly specific ways. In sickle cell disease, one major strategy is to increase fetal hemoglobin production, a form that does not sickle.",[36,1627,1628],{},[60,1629],{"alt":1630,"className":1631,"src":1632,"style":66},"Figure 1. CRISPR-Cas9 gene editing system. Guide RNA directs Cas9 to a specific DNA sequence, where Cas9 introduces a double-strand break at the target site.\nAdapted from Redman et al. (2016).\n",[64],"\u002Fnewsletter\u002Fcasgevy\u002Ffig1.png",[36,1634,1630],{"className":1635},[71,70],[36,1637,1638],{},"Casgevy, formally known as exagamglogene autotemcel, became the first CRISPR-based therapy approved by the U.S. Food and Drug Administration in 2023, as shown in Figure 3. Its approval marked a turning point in biomedical science: gene editing moved from controlled laboratory experimentation into regulated clinical medicine, directly impacting many patients.",[36,1640,1641],{},[60,1642],{"alt":1643,"className":1644,"src":1645,"style":66},"Figure 2. Normal versus sickle red blood cells in sickle cell disease. Sickled red blood cells can obstruct blood flow in small vessels, reducing oxygen delivery to tissues.\nAdapted from HealthLink BC (2022).",[64],"\u002Fnewsletter\u002Fcasgevy\u002Ffig2.png",[36,1647,1649],{"className":1648},[71,70],"\nFigure 2. Normal versus sickle red blood cells in sickle cell disease. Sickled red blood cells can obstruct blood flow in small vessels, reducing oxygen delivery to tissues.\nAdapted from HealthLink BC (2022).\n",[12,1651,1653],{"id":1652},"biological-foundations-from-molecular-mechanism-to-clinical-outcome","Biological Foundations: From Molecular Mechanism to Clinical Outcome",[36,1655,1656],{},"Gene regulation therapies add another layer of control over hemoglobin production. A key regulator of this process is the BCL11A gene, which suppresses fetal hemoglobin expression after infancy. In sickle cell disease therapy, this pathway becomes an important target: reducing BCL11A activity allows fetal hemoglobin production to persist into adulthood, providing an alternative oxygen-carrying mechanism that does not undergo sickling.",[36,1658,1659],{},"Natural DNA repair pathways also play an important role in how genetic changes are established within cells. Non-homologous end joining (NHEJ) repairs broken DNA ends but can introduce small insertions or deletions that alter gene function, while homology-directed repair (HDR) uses a template to make more precise genetic changes. Together, these processes influence how modifications to DNA are integrated and how gene activity is ultimately affected.",[36,1661,1662],{},"Together, these regulatory and repair systems form the biological foundation for modern gene-editing approaches in sickle cell disease. By utilizing the cell’s own control and repair machinery, targeted interventions can reduce BCL11A activity and increase fetal hemoglobin production in hematopoietic stem cells.",[36,1664,1665],{},"These mechanisms underpin CRISPR-based therapeutic strategies such as Casgevy, which targets the BCL11A regulatory pathway to produce sustained increases in fetal hemoglobin and reduce red blood cell sickling.",[36,1667,1668],{},[60,1669],{"alt":1670,"className":1671,"src":1672,"style":66},"Figure 3. CRISPR-Cas9 gene editing process showing how the system identifies a specific DNA sequence and modifies it, leading to a change in gene function.\nAdapted from Jiang and Doudna (2017).",[64],"\u002Fnewsletter\u002Fcasgevy\u002Ffig3.png",[36,1674,1676],{"className":1675},[71,70],"\nFigure 3. CRISPR-Cas9 gene editing process showing how the system identifies a specific DNA sequence and modifies it, leading to a change in gene function.\nAdapted from Jiang and Doudna (2017).\n",[36,1678,1679],{},"Casgevy uses an ex vivo approach, meaning gene editing occurs outside the body. Hematopoietic stem cells are collected from the patient, modified using CRISPR to target the BCL11A regulatory pathway, and then reinfused after conditioning therapy prepares the bone marrow. Once these edited cells engraft, they continuously produce red blood cells enriched with fetal hemoglobin, reducing sickling and improving oxygen delivery throughout the body.",[36,1681,1682],{},[60,1683],{"alt":1684,"className":1685,"src":1686,"style":66},"Figure 4. Ex vivo CRISPR-Cas9 gene-editing workflow in hematopoietic stem cells for sickle cell disease, including CRISPR-Cas9 targeting of the BCL11A erythroid enhancer resulting in increased fetal hemoglobin production and reduced erythrocyte sickling.\nAdapted from the National Heart, Lung, and Blood Institute (NHLBI, 2022).\n",[64],"\u002Fnewsletter\u002Fcasgevy\u002Ffig4.png",[36,1688,1690],{"className":1689},[71,70],"\nFigure 4. Ex vivo CRISPR-Cas9 gene-editing workflow in hematopoietic stem cells for sickle cell disease, including CRISPR-Cas9 targeting of the BCL11A erythroid enhancer resulting in increased fetal hemoglobin production and reduced erythrocyte sickling.\nAdapted from the National Heart, Lung, and Blood Institute (NHLBI, 2022).\n",[12,1692,1694],{"id":1693},"clinical-breakthrough-casgevy","Clinical Breakthrough: Casgevy",[36,1696,1697],{},"Exagamglogene autotemcel (Casgevy) represents the first CRISPR-based gene therapy approved for sickle cell disease. Approved in 2023 by the U.S. Food and Drug Administration, it became the first authorized treatment to use CRISPR technology in a clinical setting, establishing gene editing as a regulated therapeutic platform.",[36,1699,1700],{},"However, the body has a natural biological pathway that can counteract sickle cell disease, and Casgevy leverages this mechanism by targeting the BCL11A gene, which suppresses fetal hemoglobin production.",[36,1702,1703],{},"Casgevy uses CRISPR-Cas9 to reduce the activity of BCL11A, allowing fetal hemoglobin levels to increase and improving oxygen delivery in red blood cells. Hematopoietic stem cells are first harvested from the patient, then genetically modified outside the body using CRISPR-Cas9. After conditioning therapy clears space within the bone marrow, the edited cells are reinfused and allowed to engraft. From that point forward, they begin producing red blood cells with increased fetal hemoglobin.",[36,1705,1706],{},"Clinical trial results have shown substantial reductions in vaso-occlusive crises, which are painful episodes caused by blocked blood flow due to sickled red blood cells. By increasing fetal hemoglobin levels, the therapy reduces hemoglobin aggregation and prevents the formation of sickled cells that obstruct blood flow. Although long-term monitoring continues, early outcomes suggest durable improvement in disease severity.",[12,1708,1710],{"id":1709},"industry-cost-and-accessibility","Industry, Cost, and Accessibility",[36,1712,1713],{},"Casgevy faces a central dilemma in modern medicine: a potentially curative therapy exists, but ensuring access for patients who need it most remains a major challenge.",[36,1715,1716],{},"Despite its scientific significance, Casgevy highlights major structural limitations in modern gene therapy. The treatment requires individualized cell processing, specialized laboratory infrastructure, and tightly coordinated clinical procedures, all of which contribute to extremely high costs.",[36,1718,1719],{},"Access remains limited to specialized medical centers capable of performing stem cell extraction, genetic modification, and reinfusion. As a result, availability is uneven and largely dependent on healthcare system capacity.",[36,1721,1722],{},"At the same time, approval of Casgevy has accelerated investment in CRISPR-based biotechnology. Pharmaceutical development pipelines are increasingly focused on gene-editing therapies, while regulatory systems continue adapting to evaluate permanent genomic interventions.",[12,1724,1726],{"id":1725},"ethical-and-scientific-limitations","Ethical and Scientific Limitations",[36,1728,1729],{},"Although CRISPR-based therapies show strong clinical promise, important uncertainties remain. Researchers continue to study long-term durability of edited cells as well as the potential for unintended off-target genetic changes. Because CRISPR permanently modifies DNA, long-term monitoring is essential for evaluating safety and stability.",[36,1731,1732],{},"Ethical questions also remain central to the technology’s development. Issues of equitable access, healthcare disparity, and appropriate boundaries for genetic intervention continue to shape public and scientific discussion. While current applications focus on severe disease, the broader implications of genome editing extend far beyond current clinical use.",[36,1734,1735],{},"For these reasons, CRISPR therapies operate under strict regulatory oversight, including extensive clinical testing and long-term follow-up requirements enforced by agencies such as the FDA.",[12,1737,1739],{"id":1738},"future-implications-for-medicine-and-reearch","Future Implications for Medicine and Reearch",[36,1741,1742],{},"The success of Casgevy suggests that CRISPR-based therapies may expand to additional genetic disorders, including muscular dystrophy, cystic fibrosis, and inherited immune diseases. Ongoing improvements in gene-editing precision aim to reduce off-target effects and increase safety.",[36,1744,1745],{},"Advances in manufacturing and delivery systems may also reduce treatment costs over time, improving accessibility. At the same time, continued refinement of molecular tools is expanding the range of diseases that can be targeted at the genetic level.",[36,1747,1748],{},"More broadly, CRISPR therapy reflects a shift in medicine from symptom management toward direct modification of underlying genetic causes, representing a structural change in how disease is understood and treated at the molecular level.",[12,1750,303],{"id":302},[36,1752,1753],{},"Casgevy represents the transition of CRISPR gene editing from experimental biology to approved clinical therapy for sickle cell disease. Its development demonstrates how molecular genetics research can move into real-world medical application with measurable patient outcomes.",[36,1755,1756],{},"At the same time, it highlights persistent scientific, ethical, and economic challenges that continue to shape the future of gene-editing medicine. Questions surrounding safety, cost, and access remain central as the field evolves.",[36,1758,1759],{},"Even with these limitations, Casgevy marks a defining milestone in modern biomedical science. As CRISPR-based therapies expand, they are likely to reshape not only how genetic disease is treated, but how it is fundamentally understood.",[12,1761,322],{"id":321},[324,1763,1764,1771,1779,1786,1793,1800,1807,1814,1821,1828,1835],{},[20,1765,1766,1767],{},"Frangoul, H., Altshuler, D., Cappellini, M. D., et al. (2021). CRISPR-Cas9 gene editing for sickle cell disease and β-thalassemia. New England Journal of Medicine, 384(3), 252–260. ",[330,1768,1769],{"href":1769,"rel":1770},"https:\u002F\u002Fwww.nejm.org\u002Fdoi\u002Ffull\u002F10.1056\u002FNEJMoa2031054",[334],[20,1772,1773,1774,1778],{},"Jiang, F., & Doudna, J. A. (2017). CRISPR–Cas9 structures and mechanisms. Annual Review of Biophysics, 46, 505–529. ",[330,1775,1776],{"href":1776,"rel":1777},"https:\u002F\u002Fwww.annualreviews.org\u002Fcontent\u002Fjournals\u002F10.1146\u002Fannurev-biophys-062215-010822",[334],"\nHealthLink BC. (2022). Sickle cell disease.",[20,1780,1781,1782],{},"Healthwise. ",[330,1783,1784],{"href":1784,"rel":1785},"https:\u002F\u002Fwww.healthlinkbc.ca\u002Fhealth-library\u002Fhealth-topics\u002Fsickle-cell-disease",[334],[20,1787,1788,1789],{},"Locatelli, F., Lang, P., Wall, D., et al. (2024). Exagamglogene autotemcel for severe sickle cell disease. New England Journal of Medicine, 390(18), 1649–1662. ",[330,1790,1791],{"href":1791,"rel":1792},"https:\u002F\u002Fwww.nejm.org\u002Fdoi\u002Ffull\u002F10.1056\u002FNEJMoa2309676",[334],[20,1794,1795,1796],{},"National Center for Biotechnology Information. (2023). Efficacy and safety of a single dose of exagamglogene autotemcel for transfusion-dependent β-thalassemia and severe sickle cell disease. ",[330,1797,1798],{"href":1798,"rel":1799},"https:\u002F\u002Fpmc.ncbi.nlm.nih.gov\u002Farticles\u002FPMC10112499\u002F",[334],[20,1801,1802,1803],{},"National Heart, Lung, and Blood Institute (NHLBI). (2022). Genetic therapies for blood and immune conditions. U.S. National Institutes of Health. ",[330,1804,1805],{"href":1805,"rel":1806},"https:\u002F\u002Fwww.nhlbi.nih.gov\u002Fhealth\u002Fgenetic-therapies\u002Ftreatments",[334],[20,1808,1809,1810],{},"New England Journal of Medicine. (2021). Post-transcriptional genetic silencing of BCL11A to treat sickle cell disease. ",[330,1811,1812],{"href":1812,"rel":1813},"https:\u002F\u002Fwww.nejm.org\u002Fdoi\u002Ffull\u002F10.1056\u002FNEJMoa2029392",[334],[20,1815,1816,1817],{},"Pharmaceutical Technology. (2024). Casgevy: Launch sequence and price analysis of the first marketed CRISPR therapy. ",[330,1818,1819],{"href":1819,"rel":1820},"https:\u002F\u002Fwww.pharmaceutical-technology.com\u002Fpricing-and-market-access\u002Fcasgevy-launch-crispr-therapy\u002F",[334],[20,1822,1823,1824],{},"Redman, M., King, A., Watson, C., & King, D. (2016). What is CRISPR\u002FCas9? Archives of Disease in Childhood: Education and Practice, 101(4). ",[330,1825,1826],{"href":1826,"rel":1827},"https:\u002F\u002Fdoi.org\u002F10.1136\u002Farchdischild-2016-310459",[334],[20,1829,1830,1831],{},"U.S. Food and Drug Administration. (2023). Casgevy. ",[330,1832,1833],{"href":1833,"rel":1834},"https:\u002F\u002Fwww.fda.gov\u002Fvaccines-blood-biologics\u002Fcasgevy",[334],[20,1836,1837,1838],{},"Suhail, M. (2024). Biophysical chemistry behind sickle cell anemia and the mechanism of voxelotor action. Scientific Reports, 14, 1861. ",[330,1839,1840],{"href":1840,"rel":1841},"https:\u002F\u002Fdoi.org\u002F10.1038\u002Fs41598-024-52476-8",[334],{"title":364,"searchDepth":365,"depth":365,"links":1843},[1844,1845,1846,1847,1848,1849,1850,1851],{"id":14,"depth":365,"text":15},{"id":1652,"depth":365,"text":1653},{"id":1693,"depth":365,"text":1694},{"id":1709,"depth":365,"text":1710},{"id":1725,"depth":365,"text":1726},{"id":1738,"depth":365,"text":1739},{"id":302,"depth":365,"text":303},{"id":321,"depth":365,"text":322},"2026-06-02","Casgevy is the first FDA-approved CRISPR-based therapy for sickle cell disease - Readers will learn how sickle cell disease develops, how CRISPR-Cas9 works, and how Casgevy is applied clinically as a treatment.",{"image":1632},"\u002Fnewsletter\u002Fcasgevy",{"title":1590,"description":1853},"newsletter\u002Fcasgevy","58FxcL1E6fIuyQd2ECdFl5EJlMpyybzXlGGrdhTWdh0",{"id":1860,"title":1861,"author":1862,"body":1863,"date":1997,"description":1998,"extension":378,"meta":1999,"navigation":380,"path":2000,"seo":2001,"stem":2002,"__hash__":2003},"newsletter\u002Fnewsletter\u002Fbreastcancer.md","Young Scientists, Real Impact: How Students are Changing Women’s Health","Allison Huang",{"type":9,"value":1864,"toc":1991},[1865,1873,1876,1880,1883,1892,1895,1898,1905,1910,1914,1939,1942,1945,1948,1955,1959,1963,1972,1975,1978,1982,1985,1988],[36,1866,1867,1872],{},[330,1868,1871],{"href":1869,"rel":1870},"https:\u002F\u002Fonlinelibrary.wiley.com\u002Fdoi\u002F10.1155\u002F2018\u002F6358624",[334],"A 2018 study"," found that doctors often view men with chronic pain as “brave” or “stoic”, but women with the same conditions were called “hysterical” or were told “it’s all in your head”. Further, the legitimacy of women’s pain was often attributed to her appearance; patients were told “you can’t be sick” or “you always look so healthy”, while others were judged as unreliable if they did not look good enough. It is clear that women’s pain is repeatedly mistrusted and psychologized by the healthcare system, leading to real negligence and gaps in research surrounding women’s health and gender biases in medical technology. Even when facing conditions as severe as cancer, many women report receiving less aggressive treatment compared to men or being told to consider the impact of surgeries on their husband and future children instead of their health. However, with the recent significant progress in breast cancer research, we can move closer to gender equity.",[36,1874,1875],{},"In 2025, breast cancer research became one of the most funded types of cancer medical research, helping to spread awareness and slowly advance women’s health. For breast cancer awareness month, we wanted to highlight the growth of this field and how students are helping to take that lead. Below are high school research projects that have contributed to breast cancer research.",[12,1877,1879],{"id":1878},"study-of-forces-altering-metastatic-breast-cancer","Study of Forces Altering Metastatic Breast Cancer",[36,1881,1882],{},"It’s well known that cancer can spread, but what if that spread is being shaped by the environment the cells are moving through?",[36,1884,1885,1886,1891],{},"That’s the question ",[330,1887,1890],{"href":1888,"rel":1889},"https:\u002F\u002Fisef.net\u002Fproject\u002Fbchm017t-study-of-forces-altering-metastatic-breast-cancer",[334],"Grace Zhang and Audrey Howard asked while investigating metastatic breast cancer",", a particularly aggressive and life-threatening stage where cancer spreads beyond the original tumor site to other organs like the lungs or brain. Instead of focusing purely on genetics or cell proteins, this project considered mechanical forces: the pressures, stiffnesses, and constraints in the body that might encourage cancer cells to migrate.",[36,1893,1894],{},"Using a microfluidic model, a device that mimics the flow of fluids in the body at the microscale, they recreated different physical environments to simulate how cancer cells move through blood vessels or dense tissue. The results revealed that not only do metastatic breast cancer cells move differently under pressure, but certain force patterns can accelerate their invasion. Cells exposed to cyclical mechanical stress, for example, showed signs of increased migration, supporting that physical conditions might be just as important as biological ones in how metastasis occurs.",[36,1896,1897],{},"This research could help reshape how we understand and treat metastatic cancers. Rather than just targeting the cancer cells themselves, therapies might one day “soften” the pathways they take, literally making it harder for the disease to spread. With innovations like this coming not from a university lab, but from the next generation of scientists, breast cancer research has never looked more promising.",[36,1899,1900],{},[60,1901],{"alt":1902,"className":1903,"src":1904,"style":66},"Cancerous Cells",[64],"\u002Fnewsletter\u002Fbreatcancer\u002Fcanc.webp",[36,1906,1909],{"className":1907},[70,1908,1428,71],"italic","Photo: Shutterstock",[12,1911,1913],{"id":1912},"machine-learning-to-improve-analysis-for-breast-cancer-screening","Machine Learning to Improve Analysis for Breast Cancer Screening",[36,1915,1916,1917,1920,1921,1924,1925,1928,1929,1932,1933,1938],{},"When it comes to treating breast cancer, one of the biggest hurdles isn’t ",[90,1918,1919],{},"what"," therapies we have, it’s ",[90,1922,1923],{},"which"," therapy to use, ",[90,1926,1927],{},"when",", and for ",[90,1930,1931],{},"who",". ",[330,1934,1937],{"href":1935,"rel":1936},"https:\u002F\u002Fisef.net\u002Fproject\u002Ftmed028-machine-learning-to-improve-breast-cancer-therapy",[334],"Janie Cai used machine-learning to help tailor treatment decisions in breast cancer",", moving away from a “one size fits all” approach and toward smarter, data-driven choices. Traditional protocols rely on broad categories (tumor size, hormone receptor status, etc.), but this study asks, can we bring in many more patient-level variables and build a model that suggests the best therapy path?",[36,1940,1941],{},"Drawing from a publicly available dataset of breast cancer cases including variables like age, hormone receptor status, HER2 gene expression, and tumor stage, Janie trained several algorithms—Gradient Boosting, XGBoost, AdaBoost—to classify the most effective therapy pathway. The model chose chemotherapy, hormone therapy, or a combination, and achieved  an accuracy of around 83%, a strong performance for this kind of clinical classification.",[36,1943,1944],{},"Importantly, the results were made interpretable. She used SHAP (SHapley Additive exPlanations) values to make the model interpretable, showing which features most influenced each decision. Age, HER2, and hormone receptor status consistently ranked as the strongest predictors, reinforcing known biology, but now with individualized weighting per patient.",[36,1946,1947],{},"Why does this matter? Because current treatment decisions rely on broad clinical categories, which don’t capture the nuance of each patient’s profile. This project points toward therapy selection guided by patterns in data, helping clinicians offer more targeted, evidence based care.",[36,1949,1950],{},[60,1951],{"alt":1952,"className":1953,"src":1954,"style":66},"Cancer Grade",[64],"\u002Fnewsletter\u002Fbreatcancer\u002Fnottingham.webp",[36,1956,1958],{"className":1957},[70,1428,71],"Histological grade of breast cancer as assessed by the Nottingham Grading System. Rakha, E.A., Reis-Filho, J.S., Baehner, F. et al. Breast cancer prognostic classification in the molecular era: the role of histological grade.",[12,1960,1962],{"id":1961},"spatial-pathology-analysis-for-breast-cancer","Spatial Pathology Analysis for Breast Cancer",[36,1964,1965,1966,1971],{},"In the evolving fight against breast cancer, understanding where the disease lives inside a tumor can be as important as knowing what it is. ",[330,1967,1970],{"href":1968,"rel":1969},"https:\u002F\u002Fisef.net\u002Fproject\u002Fbmed029-spatial-pathology-analysis-for-breast-cancer",[334],"Jonathan Wang studied the architecture of cancer within the tissue",", not just the cells, but their exact positions, neighbors, and structural patterns, to uncover clues about how outcomes may differ.",[36,1973,1974],{},"Using digitized histopathology slides of breast cancer tissue, he performed analysis techniques to map the environment around the tumor. He quantified the spatial relationships between malignant, or harmful, cells, immune cells, and stromal cells (the supportive tissue around the tumor). By measuring distances, clustering behaviors,s and cell neighborhood densities, they looked for patterns that might correlate with survival rates or risk of metastasis. The project found certain spatial signatures—e.g., dense immune cell infiltration, or large regions invisible to your immune system—appeared to be linked with worse prognosis. The tissue’s layout was able to provide information that standard tumor-grading methods miss. Jonathan’s work showed that the immune cells in relation to cancer cells matter when diagnosing breast cancer.",[36,1976,1977],{},"For too long, cancer research has focused on cell-type counts or gene expression alone, often neglecting the context around it. However, tumor behavior is in part a dialogue between cancer cells and their surroundings—the immune cells trying to fight them, the stroma shielding them, and the micro-vessels feeding them. By engaging with this spatial dimension, Jonathan’s research is helping to open a new window into breast cancer biology and into more refined prognostic tools.",[12,1979,1981],{"id":1980},"the-next-chapter-in-breast-cancer-research","The Next Chapter in Breast Cancer Research",[36,1983,1984],{},"Progress in science doesn’t always look like a miracle breakthrough, or a sudden revolutionary thought. More often, it’s the culmination of new questions we ask, the tools we use, and how we can approach things differently.",[36,1986,1987],{},"What unites all three of these student-led breast cancer research projects is a fundamental rethinking of how we approach the disease. From probing the physical mechanics of cancer cell movement to using machine learning for personalized treatment, these are real, rigorous contributions to one of the most urgent frontiers in medicine.",[36,1989,1990],{},"And they come at a critical time. For decades, the science surrounding women’s health has been underfunded, under researched, and dismissed. Now, that’s changing. Breast cancer is now one of the most fast advancing fields in cancer research. And as these students show, the next generation is already making a difference. The future of breast cancer research will not be driven by any one method or model, but by a combination of ideas, all working together. And as long as we continue to support the next generation of scientists, thinkers, and engineers who are already asking the right questions, the future of women’s health will be brighter, smarter, and more equitable than it has ever been.",{"title":364,"searchDepth":365,"depth":365,"links":1992},[1993,1994,1995,1996],{"id":1878,"depth":365,"text":1879},{"id":1912,"depth":365,"text":1913},{"id":1961,"depth":365,"text":1962},{"id":1980,"depth":365,"text":1981},"2025-10-28","Advancing Gender Equity Through Breast Cancer Research",{"image":1904},"\u002Fnewsletter\u002Fbreastcancer",{"title":1861,"description":1998},"newsletter\u002Fbreastcancer","t6A1exZLfec9Ubr6odeQNDNBm2VpKPkvhGT7T9W9bLw",1789320737358]